Page last updated: 2024-11-07

celastrol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
TripterygiumgenusA plant genus of the family CELASTRACEAE that is a source of triterpenoids and diterpene epoxides such as triptolide.[MeSH]CelastraceaeA plant family of the order Celastrales, subclass Rosidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID122724
CHEBI ID63959
SCHEMBL ID14954
MeSH IDM0143971

Synonyms (89)

Synonym
AC-6031
HY-13067
34157-83-0
KBIO1_000718
DIVK1C_000718
NCI60_038570
celastrol ,
mls002701906 ,
NSC70931 ,
nsc-70931
2-picenecarboxylic acid,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydro-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-
SPECTRUM_000335
SPECTRUM4_001966
IDI1_000718
BSPBIO_001905
NCGC00178913-01
SPECTRUM5_000805
tripterin
d:a-friedo-24-noroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-, (20alpha)-
c29h38o4
tripterine
nsc 70931
KBIOGR_002436
KBIO2_003383
KBIOSS_000815
KBIO3_001405
KBIO2_005951
KBIO2_000815
SPBIO_000260
SPECTRUM2_000150
NINDS_000718
SPECTRUM3_000233
SPECTRUM201664
(2r,4as,6as,12br,14as,14br)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid
chebi:63959 ,
10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
HMS1923A13
(2r,4as,6ar,6as,14as,14br)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
A822102
SR-05000002679-3
sr-05000002679
CCG-39919
l8gg98663l ,
unii-l8gg98663l
NCGC00178913-04
(2r,4as,6as,12br,14as,14br)-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydro-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-2-picenecarboxylic acid
3-hydroxy-9beta,13alpha-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid
celastrol, celastrus scandens
CS-0409
S1290
24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-9,13-dimethyl-2-oxo-, (9.beta.,13.alpha.,14.beta.,20.alpha.)-
celastrol [mi]
24-nor-d:a-friedooleana-1(10),3,5,7-tetraen-29-oic acid, 3-hydroxy-2-oxo-
AKOS025311497
MLS006011086
smr004702874
SCHEMBL14954
(9?,13?,14?,20?)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid
Q-100413
KQJSQWZMSAGSHN-JJWQIEBTSA-N
3-hydroxy-9.beta.,13.alpha.-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid
HB4605
HMS3649E12
C2737
mfcd03424073
DTXSID2040993
bdbm205457
celastrol, >=98% (hplc), solid
GS-6082
(20alpha)-3-hydroxy-2-oxo-d:a-friedo-24-noroleana-1(10),3,5,7-tetraen-29-oic acid
SR-05000002679-1
(2r,4as,6ar,6as,14as,14br)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylicacid
NCGC00178913-02
11-alpha-hydroxyandrostenedione
BCP07973
Q5057534
34157-83-0 (castrol)
1,2,3,4,4a,5,6,6a, 11,12b,13,14,14a,14b-tetradecahydro-10-hydroxy-2,4a,6a,9,12b, 14a-hexamethyl-11-oxo-2-picenecarboxylic acid
(20alpha)-3-hydroxy-2-oxo-d:a-friedo-24-noroleana-1(10),3,5,7-tetraen-29-oate
SR-05000002679-4
HMS3884G09
H10498
24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid,3-hydroxy-9,13-dimethyl-2-oxo-, (9b,13a,14b,20a)-
compound 2 [pmid: 28621943]
gtpl10386
NCGC00178913-14
NCGC00178913-05
2-picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydro-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-, (2r,4as,6as,12br,14as,14br)-
EX-A7823

Research Excerpts

Overview

Celastrol (Cel) is a natural pentacyclic triterpene used in traditional Chinese medicine with significant weight-lowering effects. Celastrol is a promising antitumor drug candidate, but the poor water solubility and cytotoxicity limit its clinical application.

ExcerptReferenceRelevance
"Celastrol is a bioactive component of Celastrus, a traditional Chinese medicine, and it possesses anti-arthritic activity."( Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
Astry, B; Moudgil, KD; Nanjundaiah, SM; Venkatesha, SH; Yu, H, 2012
)
1.35
"Celastrol is a natural pentacyclic triterpene used in traditional Chinese medicine with significant weight-lowering effects. "( Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
Cowley, MA; De Angelis, M; Dodd, GT; Geerlof, A; Kyriakou, E; Lenhart, D; Messias, AC; Pfluger, PT; Pfuhlmann, K; Plettenburg, O; Sattler, M; Schmidt, S; Schramm, KW; Schriever, SC; Simonds, SE; Tiganis, T; Tschöp, MH, 2018
)
3.37
"Celastrol is a promising antitumor drug candidate, but the poor water solubility and cytotoxicity limit its clinical application. "( Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer.
Li, R; Sun, N; Tan, X; Tian, Q; Wu, X; Yan, M; Zeng, H; Zeng, X; Zhang, Z; Zhao, J; Zhu, X, 2022
)
3.61
"Celastrol is a novel anti-virulent agent against S. "( Celastrol mitigates staphyloxanthin biosynthesis and biofilm formation in Staphylococcus aureus via targeting key regulators of virulence; in vitro and in vivo approach.
Askoura, M; Yehia, FAA; Yousef, N, 2022
)
3.61
"Celastrol (Cel) is a naturally-derived compound with anti-cancer properties and exerts beneficial effects against various diseases. "( Quantitative chemical proteomics reveals anti-cancer targets of Celastrol in HCT116 human colon cancer cells.
Chen, X; Gao, P; Lin, Q; Liu, D; Wang, J; Wong, YK; Zhang, J; Zhang, X; Zhou, J; Zhu, Y, 2022
)
2.4
"Celastrol (Cel) is a natural anti-inflammatory compound that shows potential against systemic inflammatory diseases."( Celastrol mitigates inflammation in sepsis by inhibiting the PKM2-dependent Warburg effect.
Chen, JY; Dai, LY; Li, ZJ; Liu, JH; Luo, P; Tian, Y; Wang, JG; Yang, F; Zhang, JZ; Zhang, Q; Zheng, LH; Zhong, TY; Zou, C, 2022
)
2.89
"Celastrol is a natural compound acting as a leptin sensitizer with anti-obesity effects when administered in adult animals."( Perinatal Treatment with Leptin, but Not Celastrol, Protects from Metabolically Obese, Normal-Weight Phenotype in Rats.
Cifre, M; Oliver, P; Palou, A; Reynés, B, 2022
)
1.71
"Celastrol is a biologically active ingredient extracted from Tripterygium wilfordii that has exerted properties of anti-cancer. "( Celastrol upregulated ATG7 triggers autophagy via targeting Nur77 in colorectal cancer.
Chen, H; Chen, L; Li, Q; Mao, X; Qi, H; Shi, H; Shi, X; Wang, T; Wang, X; Wu, Z; Zhang, W; Zhong, M, 2022
)
3.61
"Celastrol (Cel) is a quinone-methylated triterpenoid extracted from Tripterygium wilfordii Hook F (TwHF) that has been proven to be effective in treating RA."( Celastrol inhibits rheumatoid arthritis by inducing autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway.
Hou, G; Jing, M; Li, J; Liu, J; Sun, H; Sun, M; Wang, C; Wang, Q; Xin, W; Yang, J; Zhang, L, 2022
)
2.89
"Celastrol is a natural bioactive compound, which has been found to possess potential antitumor activity."( Celastrol elicits antitumor effects by inhibiting the STAT3 pathway through ROS accumulation in non-small cell lung cancer.
Gong, Y; Huang, X; Li, J; Wang, L; Wang, X; Wang, Y; Yang, L; Zhang, L; Zhao, C; Zhao, H; Zhao, Z; Zhu, J, 2022
)
2.89
"Celastrol is an active monomer of Tripterygium wilfordii, and it presents an antiatopic role."( Inhibition of Mast Cell Degranulation in Atopic Dermatitis by Celastrol through Suppressing MRGPRX2.
Chen, M; Yao, C; Ye, W, 2023
)
1.87
"Celastrol (Cel) is a bioactive compound isolated from the herb Tripterygium wilfordii, which has a protective influence on cardiovascular diseases."( Celastrol confers ferroptosis resistance via AKT/GSK3β signaling in high-fat diet-induced cardiac injury.
Bian, J; Ding, Y; Jiang, Y; Shao, Y; Si, L; Wang, M; Wang, S; Wei, K; Zhao, X, 2023
)
3.07
"Celastrol is a naturally occurring chemical isolated from "( Celastrol: A Potential Natural Lead Molecule for New Drug Design, Development and Therapy for Memory Impairment.
Amir Yusri, MA; Begum, MY; Chidambaram, K; Djearamane, S; Fuloria, NK; Fuloria, S; Gan, SH; Lum, PT; Mat Rani, NNI; Ramar, M; Ravi, S; Revathy, P; Safi, SZ; Sekar, M; Selvaraj, S; Subramaniyan, V; Wong, LS; Wu, YS, 2023
)
3.8
"Celastrol is a pentacyclic triterpenoid extracted from the traditional Chinese medicine Tripterygium wilfordii Hook F., which has multiple pharmacological activities. "( Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Dai, S; Fu, K; Gong, L; Li, Y; Ma, C; Peng, C; Wang, C; Zhang, Y; Zhao, X, 2023
)
3.8
"Celastrol is a triterpene phytochemical known to possess anti‑inflammatory, antioxidant and anticancer properties. "( Celastrol enhances TRAIL‑R2‑mediated apoptosis and cytotoxicity in human renal cell carcinoma cells in caspase‑dependent manner.
Bao, Y; Kakehi, Y; Kanematsu, A; Kita, Y; Kobayashi, T; Wu, X; Yamamoto, S, 2024
)
4.33
"Celastrol is a leptin-sensitizing agent with profound anti-obesity effects in diet-induced obese (DIO) mice. "( Lipocalin 2 Does Not Play A Role in Celastrol-Mediated Reduction in Food Intake and Body Weight.
Auen, T; Choi, JW; Copps, KD; Faruk, F; Feng, X; Guan, D; Ozcan, U; Salazar-Hernandez, MA, 2019
)
2.23
"Celastrol is a promising anti-obesity agent that acts as a sensitizer of the protein hormone leptin. "( Integrating pathway elucidation with yeast engineering to produce polpunonic acid the precursor of the anti-obesity agent celastrol.
Andreadelli, A; Bak, S; Hansen, NL; Ignea, C; Kampranis, SC; Makris, AM; Miettinen, K; Møller, BL; Raadam, MH; Stærk, D; Zhao, Y, 2020
)
2.21
"Celastrol is a potent bioactive medicine which can exert anti-inflammatory and anti-oxidative effects in various diseases."( Chondro-protective effects of celastrol on osteoarthritis through autophagy activation and NF-κB signaling pathway inhibition.
Chen, H; Feng, K; Xu, C, 2020
)
1.57
"Celastrol is a natural product from traditional Chinese medicine which has been used in treating liver cancer."( Celastrol inhibits ezrin-mediated migration of hepatocellular carcinoma cells.
Cao, Y; Chen, Y; Cheng, J; Chu, F; Ding, X; Du, S; Durojaye, OA; Gao, X; Li, Y; Liu, X; Shi, X; Song, X; Su, Z; Wang, D; Wang, F; Wang, J; Wang, T; Zeng, W, 2020
)
2.72
"Celastrol is a quinine methide triterpenoid isolated from the root bark of traditional Chinese herb Tripterygium wilfordii."( Celastrol suppresses lipid accumulation through LXRα/ABCA1 signaling pathway and autophagy in vascular smooth muscle cells.
Gong, Y; Jiang, S; Liao, D; Qin, L; Shi, Y; Zhao, T, 2020
)
2.72
"Celastrol functions as a potential therapeutic substance, acting via the PI3K/AKT pathway to attenuate renal injury, inhibit glomerular basement membrane thickening, and achieve podocyte homeostasis in diabetic nephropathy."( Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway.
Fan, X; Fu, C; Hou, Z; Li, Y; Nie, Y; Tong, X; Xie, H; Yan, M; Zhang, H; Zhang, M, 2020
)
3.44
"Celastrol is a quinone-methide triterpenoid isolated from the root extracts of Tripterygium wilfordii (Thunder god vine). "( Biotransformation of celastrol to a novel, well-soluble, low-toxic and anti-oxidative celastrol-29-O-β-glucoside by Bacillus glycosyltransferases.
Chang, TS; Chen, HL; Chiang, CM; Lin, YJ; Ting, HJ; Wang, TY; Wu, JY; Wu, YW, 2021
)
2.38
"Celastrol is a triterpene derived from the traditional Chinese medicine Tripterygium wilfordii Hook f, which displays potential anticancer activity. "( Celastrol induces lipophagy via the LXRα/ABCA1 pathway in clear cell renal cell carcinoma.
Liao, DF; Liu, BY; Long, J; Qin, L; Wang, YX; Wu, HT; Zhang, CJ; Zhu, N, 2021
)
3.51
"Celastrol is a triterpene extracted from the Tripterygium wilfordii that exhibits potential anticancer activity."( Ferroptosis inducer erastin sensitizes NSCLC cells to celastrol through activation of the ROS-mitochondrial fission-mitophagy axis.
Cao, P; Chang, Y; Chen, F; Fan, Y; Han, B; Han, Y; Huang, L; Li, D; Liu, M; Liu, T; Meng, Y; Nakai, A; Song, Z; Tan, K, 2021
)
1.59
"Celastrol is a promising therapeutic agent for the treatment of osteoarthritis (OA). "( Comparative transcriptomics and network pharmacology analysis to identify the potential mechanism of celastrol against osteoarthritis.
Dai, S; Lin, Z; Wang, H; Wang, M; Zhang, Y; Zhang, Z, 2021
)
2.28
"Celastrol (Cel) is a quinone-methylated triterpenoid extracted from Tripterygium wilfordii that is used to treat RA."( Celastrol inhibits rheumatoid arthritis through the ROS-NF-κB-NLRP3 inflammasome axis.
Hou, G; Jing, M; Liu, J; Sun, Y; Wang, C; Wang, M; Xin, W; Xu, S; Yan, W; Yang, J; Zhang, L, 2021
)
2.79
"Celastrol is a plant-derived triterpene which showed neuroprotective potential in several types of brain insults."( Celastrol protects against early brain injury after subarachnoid hemorrhage in rats through alleviating blood-brain barrier disruption and blocking necroptosis.
Cai, J; Cai, Y; Chen, G; Chen, J; Chen, T; Gu, C; Hu, X; Jie, L; Li, J; Qin, B; Shen, Y; Sun, J; Wang, C; Wang, L; Xu, D; Xu, H; Ying, G; Yu, M, 2021
)
2.79
"Celastrol is a pentacyclic triterpenoid derived from the root extracts of Tripterygium wilfordii that possesses potent anti-inflammatory properties in a number of animal models with metabolic diseases."( Improvement of mitochondrial function by celastrol in palmitate-treated C2C12 myotubes via activation of PI3K-Akt signaling pathway.
Abu Bakar, MH; Tan, JS, 2017
)
1.44
"Celastrol is a natural triterpenoid derived from Tripterygium wilfordii Hook F."( Celastrol ameliorates acetaminophen-induced oxidative stress and cytotoxicity in HepG2 cells.
Alpertunga, B; Jannuzzi, AT; Kara, M, 2018
)
2.64
"Celastrol is an anti-inflammatory natural triterpenoid, isolated from the herb Tripterygium wilfordii or thunder god vine. "( Potent suppression of both spontaneous and carcinogen-induced colitis-associated colorectal cancer in mice by dietary celastrol supplementation.
Barker, EC; Choi, SH; Kim, BG; Letterio, JJ; Tochtrop, GP; Yoon, JH, 2018
)
2.13
"Celastrol (CST) is a promising natural drug of herbal origin that gained a great interest in the recent years by virtue of its wide variety of pharmacological actions. "( Self-assembled phospholipid-based phytosomal nanocarriers as promising platforms for improving oral bioavailability of the anticancer celastrol.
Abdallah, OY; Freag, MS; Saleh, WM, 2018
)
2.13
"Celastrol is a highly investigated anticancer moiety. "( Celastrol as a pentacyclic triterpenoid with chemopreventive properties.
Das, SK; Garg, VK; Jaswal, V; Kashyap, D; Sharma, A; Srinivas, R; Tuli, HS; Yadav, P, 2018
)
3.37
"Celastrol is a natural compound that exhibits antiproliferative activity."( Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
Cao, F; Chen, H; Chen, Q; Liu, Q; Peng, B; Uzan, G; Wang, Y; Xu, L; You, J; Zhang, D; Zhang, X, 2018
)
2.64
"Celastrol is an active ingredient of Chinese medicine Tripterygium wilfordii which is clinically used to treat the immune diseases. "( Celastrol ameliorates cisplatin nephrotoxicity by inhibiting NF-κB and improving mitochondrial function.
Ding, G; Huang, S; Jia, Z; Meng, X; Xu, M; Yu, X; Zhang, A; Zhang, X; Zhang, Y, 2018
)
3.37
"Celastrol is a triterpenoid quinine methide that exerts important biological effects on a variety of disease models. "( Celastrol Ameliorates Inflammation in Human Retinal Pigment Epithelial Cells by Suppressing NF-κB Signaling.
Li, Z; Shang, F; Zhang, J; Zhang, X; Zhou, K; Zhou, Y, 2019
)
3.4
"Celastrol is a pentacyclic triterpenoid isolated from the Chinese herbal medicine Trypterygium wilfordii, which has therapeutic potential in multiple diseases."( Celastrol induces vincristine multidrug resistance oral cancer cell apoptosis by targeting JNK1/2 signaling pathway.
Chen, MK; Chuang, YC; Hsi, YT; Hsieh, MJ; Lin, CC; Lin, FZ; Lin, SH; Lo, YS; Wang, SC, 2019
)
2.68
"Celastrol is a promising bioactive compound isolated from Tripterygium wilfordii and has been shown to possess many encouraging preclinical applications. "( Friedelane-type triterpene cyclase in celastrol biosynthesis from Tripterygium wilfordii and its application for triterpenes biosynthesis in yeast.
Chen, S; Gao, L; Gao, W; Hu, T; Huang, L; Song, Y; Su, P; Tu, L; Wang, X; Zhang, Y; Zhao, Y; Zhou, J, 2019
)
2.23
"Celastrol is a natural compound isolated from the root of Tripterygium wilfordii."( Celastrol Protects RPE Cells from Oxidative Stress-Induced Cell Death via Activation of Nrf2 Signaling Pathway.
Shang, F; Zhang, J; Zhang, X; Zhou, K; Zhou, L; Zhou, Y, 2019
)
2.68
"Celastrol is a direct modulator of the progesterone and cannabinoid receptors, and its effects correlate with the antiproliferative activity."( Dissecting celastrol with machine learning to unveil dark pharmacology.
Barbosa-Morais, NL; Bernardes, GJL; de Almeida, BP; Rodrigues, T, 2019
)
1.63
"Celastrol is a major active ingredient of Tripterygium wilfordii, which can increase the antitumor effect of traditional antitumor drugs."( Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.
Chen, Z; Kong, LC; Wei, P; Wu, SS; Xu, J; Zhang, R, 2019
)
2.68
"Celastrol is a pleiotropic compound from a traditional Chinese medicine that has proven to be useful as a sensitizer for TRAIL treatment."( Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha, Z; Cheng, J; He, Y; Jia, J; Peng, Z; Qin, J; Xiang, H; Yu, H, 2019
)
2.68
"Celastrol is a well known NF-kB inhibitor, and thus may inhibit T/E fusion expressing PCa cell growth."( Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.
Bai, Y; Cai, Y; Castro, P; Dakhov, O; Ji, H; Shao, L; Shen, W; Shi, P; Wang, J; Zhou, Z, 2013
)
2.55
"Celastrol is a triterpenoid compound extracted from the Chinese herb Tripterygium wilfordii Hook F. "( Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress.
Bai, W; Ferro, A; Gu, L; Gu, Y; Han, Y; Ji, Y; Li, S; Meng, G; Shan, L; Wang, J; Wei, L; Xiao, Y; Xie, L; Zhang, Y; Zhou, S, 2013
)
3.28
"Celastrol is a potent inflammation inhibitor that has little toxicity."( Celastrol protects kidney against ischemia-reperfusion-induced injury in rats.
Chu, C; Gou, X; He, W; Kuang, Y; Ren, K, 2014
)
2.57
"Celastrol is an active compound extracted from the root bark of the traditional Chinese medicine Tripterygium wilfordii Hook F. "( Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation.
Kong, X; Li, H; Ni, H; Ouyang, J; Zhao, W, 2014
)
3.29
"Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially HSP70, this effect believed to reduce its anti-tumor effects. "( Peptide deformylase inhibitor actinonin reduces celastrol's HSP70 induction while synergizing proliferation inhibition in tumor cells.
Cao, F; Cao, L; Li, M; Peng, B; Uzan, G; Wang, Y; Xu, L; Yang, C; Zhang, D; Zhang, X, 2014
)
2.1
"Celastrol is a potential agent to counter this neurodegenerative disorder as recent evidence indicates that in vivo administration of celastrol in a transgenic model of Alzheimer's reduces an important neuropathological hallmark of this disease, namely, amyloid beta pathology that involves protein aggregation."( Localization of heat shock proteins in cerebral cortical cultures following induction by celastrol.
Brown, IR; Chow, AM; Hanif, A; Tang, DW, 2014
)
1.35
"Celastrol is an active compound extracted from the root bark of the traditional Chinese medicine Tripterygium wilfordii Hook F. "( NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis.
Kong, X; Li, H; Ni, H; Ouyang, J; Zhao, W, 2014
)
2.12
"Celastrol is a neuroprotective agent with anti-inflammatory and antioxidant properties."( Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Czarnecka, A; Domin, H; Jantas, D; Konieczny, J; Kuter, K; Lasoń, W; Lenda, T; Lorenc-Koci, E; Śmiałowska, M, 2014
)
1.4
"Celastrol is a plant-derived pentacyclic triterpenoid compound with potent antioxidant, anti-inflammatory and anticancer activities; however, celastrol's action mode is still elusive."( The effect of celastrol, a triterpene with antitumorigenic activity, on conformational and functional aspects of the human 90kDa heat shock protein Hsp90α, a chaperone implicated in the stabilization of the tumor phenotype.
Alves, FR; Ramos, CH; Zanphorlin, LM, 2014
)
1.48
"Celastrol is a quinone methide triterpene derived from Tripterygium wilfordii Hook F., a plant used in traditional medicine. "( Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9.
Han, LZ; Jin, X; Lee, JJ; Ma, J; Mi, C; Shi, H, 2014
)
3.29
"Celastrol is a natural terpenoid isolated from Tripterygium wilfordii, a well-known Chinese medicinal herb that presents anti-proliferative activities in several cancer cell lines. "( Celastrol induces mitochondria-mediated apoptosis in hepatocellular carcinoma Bel-7402 cells.
He, W; Li, PP; Lu, JT; Song, SS; Wei, W; Yuan, PF, 2015
)
3.3
"Celastrol is a quinone methyl terpene extracted from the traditional Chinese medicine Tripterygium wilfordii, which has anti-inflammatory, immune suppression and pharmacological activities, as well as anti-tumor activity. "( [Anti-metastasis of celastrol on esophageal cancer cells and its mechanism].
Wu, CL; Xu, J, 2015
)
2.18
"Celastrol is a bioactive compound isolated from T."( Celastrol blocks binding of lipopolysaccharides to a Toll-like receptor4/myeloid differentiation factor2 complex in a thiol-dependent manner.
Kim, ND; Lee, BH; Lee, JY, 2015
)
2.58
"Celastrol is an active compound extracted from the root bark of Triptergium wilfordii Hook F., also known as ̔Thunder of God Vine̓. "( Celastrol induces apoptosis of human osteosarcoma cells via the mitochondrial apoptotic pathway.
Dai, M; Fu, C; Guo, R; Liu, H; Nie, T; Wang, Q; Yu, X; Zhang, B; Zhou, X; Zou, F, 2015
)
3.3
"Celastrol is a traditional herbal medicine known for its anti-inflammatory and anti-cancer activities."( Sugar-decorated mesoporous silica nanoparticles as delivery vehicles for the poorly soluble drug celastrol enables targeted induction of apoptosis in cancer cells.
Desai, D; Eriksson, JE; Niemelä, E; Nkizinkiko, Y; Rosenholm, JM, 2015
)
1.36
"Celastrol is a type of quinone methyl triterpene isolated from traditional Chinese medicine Tripterygium wilfordii, with pharmacological activities, like anti-inflammatory, immunosuppression and anti-tumor. "( [Effect of celastrol in inhibiting metastasis of lung cancer cells by influencing Akt signaling pathway and expressing integrins].
Huang, J; Wu, CL; Xu, J, 2015
)
2.25
"Celastrol is a novel anti-tumor agent. "( Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol.
Cao, F; Cao, L; Peng, B; Shen, Y; Uzan, G; Wang, Y; Yang, C; Zhang, D; Zhang, X, 2015
)
2.07
"Celastrol is an important bioactive triterpenoid in traditional Chinese medicinal plant, Tripterygium wilfordii. "( The MVA pathway genes expressions and accumulation of celastrol in Tripterygium wilfordii suspension cells in response to methyl jasmonate treatment.
Gao, W; Hu, TY; Huang, LQ; Liu, YJ; Su, P; Tong, YR; Zhang, M; Zhao, YJ, 2016
)
2.13
"Celastrol is a potent immunosuppressive and anti-inflammatory agent."( Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-κB Signaling Pathway in Type 2 Diabetic Rats.
Chen, LM; Guan, Y; Han, LP; Li, CJ; Ma, ZJ; Sun, B; Xie, Y, 2016
)
1.47
"Celastrol is a bioactive compound derived from traditional Chinese medicinal herbs of the Celastraceae family. "( Control of autoimmune inflammation by celastrol, a natural triterpenoid.
Astry, B; Dudics, S; Moudgil, KD; Venkatesha, SH, 2016
)
2.15
"Celastrol is a quinone methide triterpene and the most abundant bioactive constituent isolated from the root extracts of T. wilfordii."( Celastrol inhibits dengue virus replication via up-regulating type I interferon and downstream interferon-stimulated responses.
Hsieh, CL; Hsu, YC; Lee, JC; Lin, CK; Tseng, CK; Wu, YH; Yu, JS, 2017
)
2.62
"Celastrol is a natural triterpene used as a treatment for inflammatory conditions."( Inhibition of IKKβ by celastrol and its analogues - an in silico and in vitro approach.
Ethiraj, P; Natarajan, S; Samuel, S; Veerappan, K; Vetrivel, U, 2017
)
1.49
"Celastrol is an active ingredient of traditional herbal medicine and has recently been identified as a potent natural proteasome inhibitor. "( Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer.
Dai, Y; DeSano, JT; Ji, Q; Lawrence, TS; Ljungman, M; Meng, Y; Xu, L, 2009
)
3.24
"Celastrol is an active ingredient of the traditional Chinese medicinal plant, Tripterygium wilfordii Hook F, which is known especially for its anti-inflammatory effects. "( Celastrol, a triterpene extracted from Tripterygium wilfordii Hook F, inhibits platelet activation.
Bassler, N; Cheng, J; Hu, H; Peter, K; Straub, A; Tian, Z, 2009
)
3.24
"Celastrol is a major active component of Tripterygium wilfordii named "Thunder God Vine", which is widely used to treat rheumatoid arthritis in China. "( Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study.
Huang, YL; Zhou, YX, 2009
)
2.1
"Celastrol is a terpenoid purified from Tripterygium wilfordii Hook F. "( Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio).
Chen, X; He, Q; Liu, K; Wang, S; Wang, X, 2011
)
2.15
"Celastrol is a natural proteasome inhibitor that exhibits promising anti-tumor effects in human malignancies, especially the androgen-independent prostate cancer (AIPC) with constitutive NF-κB activation. "( Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB.
Burstein, E; Dai, Y; Desano, J; Lawrence, TS; Meng, X; Meng, Y; Tang, W; Xu, L, 2010
)
2.09
"Celastrol is a natural compound extracted from the traditional Chinese medicinal herb, Tripterygium wilfordii Hook. "( Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways.
Bao, H; Fang, W; Mou, H; Xu, N; Zhao, P; Zheng, Y, 2011
)
3.25
"Celastrol is an active ingredient of the traditional Chinese medicinal plant Tripterygium Wilfordii, which exhibits significant antitumor activity in different cancer models in vitro and in vivo; however, the lack of information on the target and mechanism of action of this compound have impeded its clinical application. "( Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells.
Chen, G; Cheng, X; Du, Z; Wang, D; Wang, Y; Xu, Y; Yu, X; Zhang, X; Zhao, M, 2011
)
3.25
"Celastrol is a quinone methide triterpene derived from the medicinal plant Tripterygium wilfordii, which has been used to treat chronic inflammatory and autoimmune diseases."( Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-κB pathway.
Kizaki, M; Sagawa, M; Tozawa, K, 2011
)
1.38
"Celastrol is a potential agent for clinical use in preventing the invasion and metastasis of human malignant breast tumors."( Celastrol inhibits breast cancer cell invasion via suppression of NF-ĸB-mediated matrix metalloproteinase-9 expression.
Jang, SW; Kang, H; Kim, Y; Ko, J, 2011
)
2.53
"Celastrol (CSL) is a naturally occurring triterpenoid acid that exhibits anticancer activity, and in KU7 and 253JB-V bladder cells, CSL induced apoptosis, inhibited growth, colony formation and migration and CSL decreased bladder tumor growth in vivo. "( Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells.
Chadalapaka, G; Jutooru, I; Safe, S, 2012
)
3.26
"Celastrol is a natural compound extracted from the traditional Chinese medicinal herb, Thunder God Vine (TGV). "( Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats.
Chu, JH; Ju, WZ; Li, CY; Liu, SJ; Wu, T; Xu, MJ; Zhang, J, 2012
)
2.06
"Celastrol, which is a triterpene purified from Celastraceae plants, has anticancer and anti-inflammatory activities. "( Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol.
Nagase, M; Oto, J; Sakato, N; Sugiyama, S; Takaishi, Y; Yube, K, 2003
)
1.99
"Celastrol is a potent anti-inflammatory and antioxidant compound extracted from a perennial creeping plant belonging to the Celastraceae family."( Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity.
Beal, MF; Calingasan, NY; Chen, J; Cleren, C, 2005
)
2.49
"Celastrol is a natural product from Southern China, which exerts potent anti-inflammatory and antioxidative effects."( Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis.
Beal, MF; Calingasan, NY; Chen, J; Kiaei, M; Kipiani, K; Petri, S, 2005
)
2.49

Effects

Celastrol (CEL) has a great potential in the treatment of a wide variety of metabolic diseases. It has an anticancer effect, but its mechanism needs to be determined.

Celastrol has been found to be a potent anti-inflammatory and antitumor plant derivative. The precise mechanism underlying ROS-mediated mitochondria-dependent cell death triggered by celastrol treatment in melanoma cells remains unknown. Celastrol was used for treatment of autoimmune disease, chronic inflammation and neurodegenerative disease.

ExcerptReferenceRelevance
"Celastrol (CEL) has a great potential in the treatment of a wide variety of metabolic diseases. "( Celastrol inhibits TXNIP expression to protect pancreatic β cells in diabetic mice.
Chen, HF; Huang, H; Lan, T; Wang, SW; Wu, Q; Zhang, F; Zheng, F, 2022
)
3.61
"Celastrol has an anticancer effect, but its mechanism needs to be determined."( Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway.
Bufu, T; Di, X; Gege, L; Ling, W; Xi, C; Yilin, Z, 2018
)
2.64
"Celastrol (CLT) has shown anti-rheumatic activity against rheumatoid arthritis, while its poor water solubility and high organ toxicity restrict its further therapeutic applications. "( Reactive Oxygen Species-Responsive Celastrol-Loaded : Bilirubin Nanoparticles for the Treatment of Rheumatoid Arthritis.
Huang, C; Ran, Y; Su, M; Wang, Y; Yin, Z; Zhao, X, 2021
)
2.34
"Celastrol has attracted great attention owing to its anti-arthritis, antioxidant, and anticancer activities. "( A comprehensive study of celastrol metabolism in vivo and in vitro using ultra-high-performance liquid chromatography coupled with hybrid triple quadrupole time-of-flight mass spectrometry.
Chen, YT; Feng, X; Li, LY; Song, KW; Sun, YP; Zhang, GH; Zhang, LT; Zhang, XW, 2022
)
2.47
"Celastrol (CEL) has a great potential in the treatment of a wide variety of metabolic diseases. "( Celastrol inhibits TXNIP expression to protect pancreatic β cells in diabetic mice.
Chen, HF; Huang, H; Lan, T; Wang, SW; Wu, Q; Zhang, F; Zheng, F, 2022
)
3.61
"Celastrol have been found to regulate AGE-RAGE, TNF, MAPK, TOLL-like receptors, insulin resistance, and other signaling pathways, and they are closely linked to adipocytokines, fatty acid metabolism, glycolipid biosynthesis, and glycosylphosphati-dylinositol biosynthesis on DCM."( Investigating Celastrol's Anti-DCM Targets and Mechanisms via Network Pharmacology and Experimental Validation.
Chai, R; Li, S; Mu, F; Sun, Q; Wan, Y; Wu, Z; Xi, R; Yan, R; Yang, L; Yang, S; Zhang, J, 2022
)
1.8
"Celastrol has powerful anti-inflammatory property and has achieved good results in various inflammation-related diseases."( Celastrol-encapsulated microspheres prepared by microfluidic electrospray for alleviating inflammatory pain.
Cao, J; Lu, Y; Qin, Z; Tao, T; Wang, H; Zeng, F; Zhao, C; Zheng, H, 2023
)
3.07
"Celastrol (CL) has exhibited anti-inflammatory activities in various inflammatory traits though underlying mechanisms remain unknown."( Celastrol Treatment Ameliorated Acute Ischemic Stroke-Induced Brain Injury by Microglial Injury Inhibition and Nrf2/HO-1 Pathway Activations.
Cao, F; Jiang, M; Liu, X; Song, Y; Wang, Y; Xie, Q; Xu, F; Xu, L; Zhang, D, 2023
)
3.07
"Celastrol has been identified as a potential candidate for anticancer drug development. "( Design, synthesis, and evaluation of antitumor activity of novel C-6 sulfhydryl-substituted and 20-substituted derivatives of celastrol.
Chen, ZJ; He, P; Huang, ST; Jiang, N; Long, JY; Qin, XQ; Su, D; Tang, WZ; Wei, RY; Yan, YQ; Yan, ZM; Zhang, FL; Zhong, GH, 2023
)
2.56
"Celastrol (Cel) has been corroborated as an anti-inflammatory and anti-apoptotic agent in multiple cell damage models. "( Celastrol mitigates high glucose-induced inflammation and apoptosis in rat H9c2 cardiomyocytes via miR-345-5p/growth arrest-specific 6.
Cao, Y; Li, K; Ma, L; Pan, Y; Yan, L; Zhang, L; Zhu, J, 2020
)
3.44
"Celastrol has been proven effective in anti-inflammatory but was limited in the clinic due to the poor solubility and side effects induced by low bioavailability. "( Intra-articular delivery of celastrol by hollow mesoporous silica nanoparticles for pH-sensitive anti-inflammatory therapy against knee osteoarthritis.
Ji, Y; Jin, T; Jin, YY; Liu, XM; Ma, BJ; Ma, K; Wu, D; Wu, SY; Wu, T; Xu, JT, 2020
)
2.29
"Celastrol (Cel) has shown antirheumatic activity against RA."( Inflammation-Targeted Celastrol Nanodrug Attenuates Collagen-Induced Arthritis through NF-κB and Notch1 Pathways.
An, L; Jin, L; Li, J; Li, Z; Shi, L; Shuai, X; Wang, L; Wang, Y, 2020
)
1.59
"Celastrol has been reported to exert therapeutic potential on pro-inflammatory diseases including asthma, Crohn's disease, arthritis and neurodegenerative disorders via inhibiting NF-κB pathway. "( Celastrol reduces IL-1β induced matrix catabolism, oxidative stress and inflammation in human nucleus pulposus cells and attenuates rat intervertebral disc degeneration in vivo.
Chen, J; Chen, JX; Chen, XB; Chen, Y; Gu, YT; Shi, KS; Wang, XY; Wu, YS; Xie, JJ; Xuan, J; Zhang, XL; Zheng, ZM, 2017
)
3.34
"Celastrol has attracted wide interests for its anticancer and anti-inflammation properties, and studies have demonstrated that celastrol negatively modulates the stromal cell-derived factor-1 (SDF-1) and receptor C-X-C chemokine receptor type 4 (CXCR4) signalling. "( Celastrol attenuates pain and cartilage damage via SDF-1/CXCR4 signalling pathway in osteoarthritis rats.
Gong, M; Ha, C; Lin, T; Wang, D; Wang, W; Wang, Y, 2018
)
3.37
"Celastrol pretreatment has been shown to protect against myocardial ischemia/reperfusion (I/R) injury, but the underlying mechanism is poorly understood. "( Celastrol pretreatment attenuates rat myocardial ischemia/ reperfusion injury by inhibiting high mobility group box 1 protein expression via the PI3K/Akt pathway.
Jiang, X; Joseph, J; Tong, S; Zhang, L, 2018
)
3.37
"Celastrol has an anticancer effect, but its mechanism needs to be determined."( Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway.
Bufu, T; Di, X; Gege, L; Ling, W; Xi, C; Yilin, Z, 2018
)
2.64
"Celastrol has been found to target multiple proinflammatory, angiogenic and metastatic proteins."( Celastrol as a pentacyclic triterpenoid with chemopreventive properties.
Das, SK; Garg, VK; Jaswal, V; Kashyap, D; Sharma, A; Srinivas, R; Tuli, HS; Yadav, P, 2018
)
2.64
"Celastrol has been shown to have potent anti-inflammatory and anti-tumor effects in multiple disease models."( Celastrol Protects RPE Cells from Oxidative Stress-Induced Cell Death via Activation of Nrf2 Signaling Pathway.
Shang, F; Zhang, J; Zhang, X; Zhou, K; Zhou, L; Zhou, Y, 2019
)
2.68
"3. Celastrol has the potential to inhibit cytochrome P450 activities and may cause the herb-drug interactions."( Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4.
An, L; Chen, J; Fan, Y; He, L; He, X; Jin, C; Wang, L; Zhang, F, 2015
)
1.23
"Celastrol has been established as a nuclear factor-κB (NF-κB) activation inhibitor; however, the exact mechanism behind this action is still unknown. "( Celastrol targets IRAKs to block Toll-like receptor 4-mediated nuclear factor-κB activation.
Cao, FF; Peng, B; Shen, YF; Uzan, G; Wang, Y; Zhang, DH; Zhang, X, 2016
)
3.32
"Celastrol has potential application for the treatment of prostate cancer. "( Downregulation of miR-17-92a cluster promotes autophagy induction in response to celastrol treatment in prostate cancer cells.
Guo, J; Huang, X; Li, K; Mei, Y; Yang, H, 2016
)
2.1
"Celastrol has shown preventive/therapeutic effects in experimental models of several chronic diseases."( Celastrol and Its Role in Controlling Chronic Diseases.
Moudgil, KD; Venkatesha, SH, 2016
)
2.6
"Celastrol has previously been used to treat rheumatoid arthritis, bruises, back pain and additional diseases. "( Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA‑21 and the suppression of the PI3K/Akt‑NF‑κB signaling pathway in an in vitro model of ovarian carcinoma.
Li, G; Li, J; Wang, S; Zhang, H, 2016
)
2.27
"Celastrol has anti-inflammatory and immunomodulatory activities, but its anti-allergic effects remain poorly understood. "( Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model.
Jeoung, D; Kim, DY; Park, JW; Ro, JY, 2009
)
3.24
"Celastrol has been proved to be an effective natural proteasome inhibitor and was used for treatment of autoimmune disease, chronic inflammation and neurodegenerative disease."( Celastrol causes apoptosis and cell cycle arrest in rat glioma cells.
Ding, Y; Fu, S; Ge, P; Ji, X; Jin, X; Ling, F; Luo, Y; Meng, F; Wang, X, 2010
)
2.52
"Celastrol has attracted great interest recently, especially for its potential anti-inflammatory and anti-cancer activities."( Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer.
Kannaiyan, R; Sethi, G; Shanmugam, MK, 2011
)
1.41
"Celastrol has been proved to elicit a vanity of biological effects through its anti-oxidant, anti-inflammatory properties in the treatment of Alzheimer's disease, systemic lupus erythematosus, and rheumatoid arthritis."( Protective effect of celastrol in rat cerebral ischemia model: down-regulating p-JNK, p-c-Jun and NF-κB.
Chen, Y; Dong, L; He, D; Li, Y; Liu, Z; Qiao, H; Wang, C; Xing, Y; Zhang, X; Zhu, C, 2012
)
1.42
"Celastrol has been found to be a potent anti-inflammatory and antitumor plant derivative recently. "( Optimized preparation of celastrol-loaded polymeric nanomicelles using rotatable central composite design and response surface methodology.
Cui, D; Li, J; Li, L; Lin, L; Liu, Y; Peng, X; Song, H; Wang, J; Zhou, J, 2012
)
2.13
"Celastrol has been reported to possess anticancer effects in various cancers; however, the precise mechanism underlying ROS-mediated mitochondria-dependent apoptotic cell death triggered by celastrol treatment in melanoma cells remains unknown. "( Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling.
Lee, JH; Lee, MK; Park, KH; Seo, KI; Tachibana, H; Won, YS; Yamada, K, 2012
)
3.26
"Celastrol has been widely used in treating inflammatory diseases in man, and is well tolerated; therefore, it may be a promising therapeutic candidate for the treatment of human ALS."( Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis.
Beal, MF; Calingasan, NY; Chen, J; Kiaei, M; Kipiani, K; Petri, S, 2005
)
2.49

Actions

Celastrol can inhibit the proliferation of SGC7901/DDP cells, induce their apoptosis, and reduce the expression of drug resistance genes. Celastrol was found to inhibit the enzymatic activity of COMT and increased the dopamine level in neuroendocrine chromaffin cells significantly.

ExcerptReferenceRelevance
"Celastrol can inhibit the proliferation and promote the apoptosis of H929 and ARP-1 cells, which may be related to inhibiting the phosphorylation of IRAK4 and blocking the activation of IRAK4/ERK/p38 signaling pathway. "( [Effect of Celastrol Based on IRAK4/ERK/p38 Signaling Pathway on Proliferation and Apoptosis of Multiple Myeloma Cells].
Chen, XL; Jiang, PJ; Kang, D; Kong, XT; Ni, HW; Xu, XM; Yu, H; Zhu, XY, 2022
)
2.55
"Celastrol was found to inhibit the enzymatic activity of COMT and increased the dopamine level in neuroendocrine chromaffin cells significantly."( Integrated Mass Spectrometry Reveals Celastrol As a Novel Catechol-O-methyltransferase Inhibitor.
Deng, JR; Guo, H; Lam, TC; Li, S; So, PK; Wong, MK; Yang, Y; Zhang, Q; Zhao, Q, 2022
)
1.72
"Celastrol can inhibit the proliferation of the SGC7901/DDP cells, induce their apoptosis, and reduce the expression of drug resistance genes, probably by inhibiting the expression of the proteins related to the mTOR signaling pathway."( Celastrol Inhibits the Proliferation and Decreases Drug Resistance of Cisplatin- Resistant Gastric Cancer SGC7901/DDP Cells.
Liu, Y; Lv, M; Ni, T; Sunagawa, M; Wang, H; Zhan, D, 2022
)
3.61
"Celastrol plays a certain role in the improvement of various diabetes complications."( Celastrol inhibits the proliferation and angiogenesis of high glucose-induced human retinal endothelial cells.
Chang, X; Fang, J, 2021
)
2.79
"Celastrol promotes Nur77 translocation from the nucleus to mitochondria, where it interacts with tumor necrosis factor receptor-associated factor 2 (TRAF2), a scaffold protein and E3 ubiquitin ligase important for inflammatory signaling."( Celastrol-Induced Nur77 Interaction with TRAF2 Alleviates Inflammation by Promoting Mitochondrial Ubiquitination and Autophagy.
Alitongbieke, G; Cai, L; Chen, H; Chen, X; Chong, S; Diaz-Meco, MT; Fang, H; Hu, M; Jiang, F; Lin, X; Liu, J; Luo, Q; Moscat, J; Su, Y; Wang, Z; Xie, L; Xu, C; Yang, S; Ye, X; Zhang, D; Zhang, F; Zhang, XK; Zhou, H; Zhou, Y, 2017
)
2.62
"Celastrol was found to inhibit the growth of colon cancer cells and induce apoptosis."( Celastrol Suppresses Tryptophan Catabolism in Human Colon Cancer Cells as Revealed by Metabolic Profiling and Targeted Metabolite Analysis.
Duan, G; Lu, F; Lv, L; Qi, Y; Wang, R; Yan, H; Zhang, T; Zhao, L; Zhou, F, 2018
)
2.64
"Celastrol plays a regulatory role in multilineage differentiation of human MSCs."( Inhibitory effect of celastrol on adipogenic differentiation of human adipose-derived stem cells.
Hong, W; Jang, J; Kang, PJ; Kim, IY; Park, J; Son, D; You, S; Yun, W, 2018
)
1.52
"Celastrol could inhibit cancer cell growth in vitro. "( Celastrol inhibits growth and metastasis of human gastric cancer cell MKN45 by down-regulating microRNA-21.
Han, L; Li, XY; Mao, T; Tian, ZB; Yang, L; Yao, SS; Yu, YN; Zhang, Q, 2019
)
3.4
"Celastrol was shown to inhibit HaCaT cells growth with an IC₅₀ value of 1.1 μM as measured by MTT assay."( Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity.
Che, CT; Cheng, CH; Fung, KP; Lin, ZX; Wu, SH; Zhao, M; Zhou, LL; Zuo, Z, 2011
)
2.53
"Celastrol, which can inhibit angiogenesis, could be developed as an antiangiogenic drug."( [Celastrol in the inhibition of neovascularization].
Du, ZW; Huang, YL; Sun, CF; Xu, QN; Ye, M; Zhou, D; Zhou, YX, 2003
)
2.67
"Celastrol can activate heat shock gene transcription synergistically with other stresses and exhibits cytoprotection against subsequent exposures to other forms of lethal cell stress."( Celastrols as inducers of the heat shock response and cytoprotection.
Bosman, JD; Devlin, JP; Gu, W; Kawahara, TL; Kim, S; Matsumoto, G; Mbadugha, BN; Morimoto, RI; Silverman, RB; Westerheide, SD, 2004
)
2.49
"Celastrol was found to inhibit the TNF-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 nuclear translocation and phosphorylation, and NF-kappaB-mediated reporter gene expression."( Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation.
Aggarwal, BB; Ahn, KS; Pandey, MK; Sethi, G, 2007
)
2.5

Treatment

Celastrol treatment significantly enhanced the suppressive effects of HDACi on lung cancer cell allografts in mice. Celastrol pretreatment attenuated oxidative stress and increased Nrf2 gene expression and HO-1 level.

ExcerptReferenceRelevance
"Celastrol-treated rats showed a significant reduction in the levels of chemokines (RANTES, MCP-1, MIP-1α, and GRO/KC) as well as cytokines (TNF-α and IL-1β) that induce them, compared to the vehicle-treated rats."( Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
Astry, B; Moudgil, KD; Nanjundaiah, SM; Venkatesha, SH; Yu, H, 2012
)
1.35
"Celastrol pretreatment attenuated oxidative stress and increased Nrf2 gene expression and HO-1 level."( The Protective Role of Celastrol in Renal Ischemia-Reperfusion Injury by Activating Nrf2/HO-1, PI3K/AKT Signaling Pathways, Modulating NF-κb Signaling Pathways, and Inhibiting ERK Phosphorylation.
Ghanim, AMH; Younis, NS, 2022
)
1.75
"Celastrol-treated cells showed deficient exopolysaccharide production and cell hydrophobicity."( Celastrol mitigates staphyloxanthin biosynthesis and biofilm formation in Staphylococcus aureus via targeting key regulators of virulence; in vitro and in vivo approach.
Askoura, M; Yehia, FAA; Yousef, N, 2022
)
2.89
"Celastrol treatment significantly enhanced the suppressive effects of HDACi on lung cancer cell allografts in mice, with significant H4K16ac upregulation, indicating that a combination of celastrol and HDACi is a potential novel therapeutic approach for patients with lung cancer."( Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors.
Chen, G; Chen, X; Li, J; Liao, W; Lu, L; Ma, L; Qin, X; Wang, J; Wang, X; Wu, W; Wu, Z; Yu, H; Zhang, R; Zhang, Y; Zhu, X, 2022
)
2.89
"Celastrol treatment protected HBMECs from OGD/R-induced cell proliferation inhibition and apoptosis and oxidative stress promotion; however, circDLGAP4 depletion attenuated these effects."( Celastrol assuages oxygen-glucose deprivation and reoxygenation-induced damage in human brain microvascular endothelial cells through the circDLGAP4/miR-6085/GDF11 pathway.
Gu, J; Liu, C; Yu, Y, 2023
)
3.07
"Celastrol treatment significantly reduced blood glucose level, body weight and food intake, and improved glucose tolerance in db/db mice. "( Celastrol targets the ChREBP-TXNIP axis to ameliorates type 2 diabetes mellitus.
Chen, B; Hassan, M; He, Q; Li, X; Liu, X; Shen, Z; Song, Y; Wang, G; Wu, L; Wu, Q; Xiao, X; Zhang, H; Zhang, L; Zhao, Y; Zhou, D; Zhou, W, 2023
)
3.8
"Celastrol treatment upregulated p21 transcription, but overexpression of high mobility group box 1 reversed this upregulation."( Celastrol induces premature ovarian insufficiency by inducing apoptosis in granulosa cells.
Kuang, W; Liu, D; Liu, G; Wang, J; Wang, M; Wen, F; Yuan, L; Zhang, S, 2023
)
3.07
"Celastrol treatment led to a significant increase in mutant PMM2 protein concentration and activity, while MG132 had a small effect on protein concentration only."( Proteostasis regulators as potential rescuers of PMM2 activity.
Desviat, LR; Gallego, D; Gámez, A; Pérez, B; Pérez-Cerda, C; Ugarte, M; Vilas, A; Yuste-Checa, P, 2020
)
1.28
"Celastrol treatment attenuated paw swelling and arthritis scores in CIA rats."( Celastrol attenuates collagen-induced arthritis via inhibiting oxidative stress in rats.
Gao, Q; Hao, X; Li, D; Qin, H; Zhu, L, 2020
)
2.72
"Celastrol pre-treatment prevents this effect of peroxynitrite."( Celastrol Prevents Oxidative Stress Effects on FSHR, PAPP, and CYP19A1 Gene Expression in Cultured Human Granulosa-Lutein Cells.
Ávila, J; González-Fernández, R; Hernández, J; Martín-Ramírez, R; Martín-Vasallo, P; Palumbo, A; Rotoli, D, 2021
)
2.79
"Celastrol-treated cells showed condensed nuclei and clumped mitochondria."( Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9.
Cheng, L; Wang, R; Xu, H; Zhang, J, 2021
)
2.79
"Celastrol treatment attenuated SAH-caused brain swelling, reduced T2 lesion volume and ventricular volume in MRI scanning, and improved overall neurological score. "( Celastrol protects against early brain injury after subarachnoid hemorrhage in rats through alleviating blood-brain barrier disruption and blocking necroptosis.
Cai, J; Cai, Y; Chen, G; Chen, J; Chen, T; Gu, C; Hu, X; Jie, L; Li, J; Qin, B; Shen, Y; Sun, J; Wang, C; Wang, L; Xu, D; Xu, H; Ying, G; Yu, M, 2021
)
3.51
"In celastrol-treated cells, N-acetylcysteine increased cell viability and phospho-NF-κB protein levels, and decreased reactive oxygen species production and cytotoxic activity."( Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ, 2017
)
1.29
"Celastrol posttreatments exerted a significant increase in the glutathione content and a decrease in the malondialdehyde and protein carbonylation levels."( Celastrol ameliorates acetaminophen-induced oxidative stress and cytotoxicity in HepG2 cells.
Alpertunga, B; Jannuzzi, AT; Kara, M, 2018
)
2.64
"Celastrol pre-treatment groups received celastrol by intraperitoneal injection on seven consecutive days before LPS treatment."( Celastrol attenuates impairments associated with lipopolysaccharide-induced acute respiratory distress syndrome (ARDS) in rats.
Wang, Y; Wei, Y, 2017
)
2.62
"Celastrol treatment stimulated RGC survival by an average of 24% in the entire retina compared to the vehicle-treated group."( The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells.
Caprioli, J; Gu, L; Kwong, JMK; Piri, N; Yadegari, D; Yu, F, 2018
)
1.56
"Celastrol pretreatment has been shown to protect against myocardial ischemia/reperfusion (I/R) injury, but the underlying mechanism is poorly understood. "( Celastrol pretreatment attenuates rat myocardial ischemia/ reperfusion injury by inhibiting high mobility group box 1 protein expression via the PI3K/Akt pathway.
Jiang, X; Joseph, J; Tong, S; Zhang, L, 2018
)
3.37
"Celastrol treatment also decreased the PI3K/AKT pathway components, and MMP3 and MMP7 expression levels."( Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway.
Bufu, T; Di, X; Gege, L; Ling, W; Xi, C; Yilin, Z, 2018
)
2.64
"Celastrol treatment inhibited the expression of stem cell marker CD44, Nanog, Klf4, and Oct4, and reduced a portion of the CD44"( Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells.
Ding, J; Li, X; Nie, S; Ren, S; Wang, H; Wang, L; Zhang, L, 2019
)
2.68
"Celastrol treatment had no impact on kindling progression but reduced postkindling seizure thresholds and enhanced microglia activation in CA1 and CA3."( Genetic and Pharmacological Targeting of Heat Shock Protein 70 in the Mouse Amygdala-Kindling Model.
Gualtieri, F; Hunt, CR; Keck, M; Pandita, TK; Potschka, H; von Rüden, EL; Wolf, F, 2019
)
1.24
"Celastrol-treated glioma cells exhibited decreased cell viability after the use of autophagy inhibitors."( Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells.
Gao, W; Liu, X; Song, Y; Wang, L; Wang, X; Zhao, P; Zhu, Y, 2019
)
2.68
"Celastrol treatment also significantly mitigated lipid accumulation and oxidative stress in organs including the kidney, liver and adipose tissue."( Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice.
Cha, DR; Cha, JJ; Han, JY; Han, KH; Han, SY; Hyun, YY; Kang, YS; Kim, HW; Kim, JE; Lee, JE; Lee, MH; Nam, DH; Song, HK, 2013
)
2.55
"Celastrol treatment inhibits migration and invasion of HCC cell and that the effect is partly due to NF-κB regulating miR-224 expression."( miR-224 is critical for celastrol-induced inhibition of migration and invasion of hepatocellular carcinoma cells.
Li, H; Li, Y; Liu, D; Liu, J; Sun, H, 2013
)
2.14
"Celastrol treatment induced an HSR through activation of HSF1 with up-regulation of HO-1 as the key effector, promoting cardiomyocyte survival, reduction of injury and adverse remodelling with preservation of cardiac function. "( Celastrol protects ischaemic myocardium through a heat shock response with up-regulation of haeme oxygenase-1.
Borie, M; Cailhier, JF; Der Sarkissian, S; Gaboury, L; Hamet, P; Mansour, S; Noiseux, N; Stevens, LM, 2014
)
3.29
"Celastrol treatment markedly increased mitochondrial Ca2+ levels and induced ER stress via proteasome inhibition in these cells."( Release of Ca2+ from the endoplasmic reticulum and its subsequent influx into mitochondria trigger celastrol-induced paraptosis in cancer cells.
Choi, KS; Jeong, SA; Kim, JY; Kim, YS; Kwon, YJ; Lee, AR; Yoon, MJ, 2014
)
1.34
"Celastrol treatment reduced Th17 cells but increased Treg in the joints, and it inhibited Th17 differentiation but promoted Treg differentiation in vitro by blocking the activation of pSTAT3."( Celastrol, a Chinese herbal compound, controls autoimmune inflammation by altering the balance of pathogenic and regulatory T cells in the target organ.
Astry, B; Christensen-Quick, A; Frieman, MB; Garzino-Demo, A; Laurence, A; Moudgil, KD; O'Shea, JJ; Venkatesha, SH, 2015
)
2.58
"Celastrol (2 mg/kg) treatment by gavage was administered to mice daily over one week."( Celastrol ameliorates experimental colitis in IL-10 deficient mice via the up-regulation of autophagy.
Dong, JN; Gong, JF; Gu, LL; Li, JS; Li, N; Li, Y; Shi, P; Sun, Y; Wang, HG; Zhao, J; Zhu, WM; Zuo, LG, 2015
)
2.58
"Celastrol treatment for four months significantly reduced the inflammation in A/J muscle; however, it had no beneficial effect in improving muscle function, as assessed by grip strength, open field activity, and in vitro force contraction."( Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice.
Ampong, B; Benny Klimek, ME; Dillingham, BC; Gallardo, E; Gernapudi, R; Gordish-Dressman, H; Jordan, S; Nagaraju, K; Rayavarapu, S; Spurney, CF; Van der Meulen, JH, 2015
)
1.42
"Celastrol treatment resulted in suppression of cell death in photoreceptor cells, alleviation of oxidative stress in the retinal pigment epithelium and photoreceptors, downregulation of retinal expression of proinflammatory genes, and suppression of microglia activation and gliosis in the retina."( Celastrol protects mouse retinas from bright light-induced degeneration through inhibition of oxidative stress and inflammation.
Bian, M; Chen, Y; Cui, J; Du, X; Wang, P; Wang, W; Zhang, T; Zhu, W, 2016
)
2.6
"Celastrol treatment significantly alleviated DSS-induced colitis in mice, as revealed by the body weight, colon length, scores of rectal bleeding and diarrhea, serum TNF-α level, and histological analysis results."( A lipidomics investigation into the intervention of celastrol in experimental colitis.
Chai, Y; Dai, W; Duan, G; Fan, G; Gonzalez, FJ; Gu, X; Lu, F; Qi, Y; Wang, R; Ye, J, 2016
)
1.41
"Celastrol-treated diabetic rats show reduced hepatic inflammation and macrophages infiltration."( Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-κB Signaling Pathway in Type 2 Diabetic Rats.
Chen, LM; Guan, Y; Han, LP; Li, CJ; Ma, ZJ; Sun, B; Xie, Y, 2016
)
1.47
"Celastrol treatment reduced the increased collagen deposition and down-regulated α-smooth muscle actin (α-SMA), atrial natriuretic peptide (ANP), brain natriuretic peptides (BNP), beta-myosin heavy chain (β-MHC), miR-21 and p-ERK/ERK. "( Celastrol-Induced Suppression of the MiR-21/ERK Signalling Pathway Attenuates Cardiac Fibrosis and Dysfunction.
Cheng, M; Song, Y; Tu, L; Wang, L; Wu, G; Zhang, C; Zhang, L, 2016
)
3.32
"Celastrol treatment also induced G2/M cell cycle arrest and apoptosis in HeLa cells."( Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90.
Feng, LX; Guan, SH; Guo, DA; Jiang, BH; Liu, X; Wang, WB; Wu, WY; Yang, M; Yue, QX, 2012
)
1.34
"Celastrol treatment significantly improved weight loss, motor performance and delayed the onset of ALS."( Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis.
Beal, MF; Calingasan, NY; Chen, J; Kiaei, M; Kipiani, K; Petri, S, 2005
)
2.49
"Treatment with celastrol significantly decreased ROS production and promoted Keap1 protein degradation through the lysosomal pathway, thereby enhancing the translocation of Nrf2 from the cytoplasm to the nucleus and increasing HO-1 expression."( Celastrol alleviates oxidative stress induced by multi-walled carbon nanotubes through the Keap1/Nrf2/HO-1 signaling pathway.
Chen, JK; Dai, XY; Qing, TL; Ren, LJ; Shi, WJ; Wang, MT; Wang, SK; Yan, L; Zhang, JQ; Zhang, XF; Zhu, JB, 2023
)
2.69
"Treatment with celastrol, which we identified as a suppressor of Bsg and CyPA by drug screening, decreased proliferation, reactive oxygen species, and inflammatory cytokines in pulmonary artery smooth muscle cells."( Identification of Celastrol as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension and Right Ventricular Failure Through Suppression of Bsg (Basigin)/CyPA (Cyclophilin A).
Kikuchi, N; Kurosawa, R; Miyata, S; Nakata, T; Nogi, M; Omura, J; Satoh, K; Satoh, T; Shimokawa, H; Shindo, T; Siddique, MAH; Sunamura, S; Takeuchi, Y, 2021
)
1.29
"Treatment with celastrol inhibited colorectal cancer cell growth and migration, and was associated with suppression of the expression of key genes (TYMP, CDH5, THBS2, LEP, MMP9, and TNF) and proteins (IL-1b, MMP-9, PDGF, Serpin E1, and TIMP-4) involved in the angiogenesis pathway."( Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer.
Gao, Y; Huo, X; Li, HJ; Pang, L; Qian, SY; Yang, J; Zhou, S, 2019
)
2.3
"Treatment with celastrol enhanced the expression of transcription factor Nrf2 and its targets, GCLM and HO-1."( Celastrol Protects RPE Cells from Oxidative Stress-Induced Cell Death via Activation of Nrf2 Signaling Pathway.
Shang, F; Zhang, J; Zhang, X; Zhou, K; Zhou, L; Zhou, Y, 2019
)
2.3
"The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), HbA1C and homeostasis model assessment index (HOMA-IR) levels."( Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice.
Cha, DR; Cha, JJ; Han, JY; Han, KH; Han, SY; Hyun, YY; Kang, YS; Kim, HW; Kim, JE; Lee, JE; Lee, MH; Nam, DH; Song, HK, 2013
)
2.15
"The treatment with celastrol significantly induced autophagy and apoptosis and increased the expression of autophagy and apoptosis-related proteins."( Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy.
Cheong, JH; Choi, HJ; Chun, KH; Jang, KS; Jo, A; Lee, HW, 2014
)
2.16
"Treatment with celastrol prevented circulatory failure (bradycardia and hypotension) 8h after LPS challenge. "( Celastrol prevents circulatory failure via induction of heme oxygenase-1 and heat shock protein 70 in endotoxemic rats.
Cheng, PY; Lam, KK; Lee, YM; Wang, YL, 2015
)
2.21
"Treatment with celastrol alone led to the decreased expressions of HSP90 client proteins including survivin, AKT, EGFR, which was enhanced by the addition of triptolide."( Synergistic anticancer effects of triptolide and celastrol, two main compounds from thunder god vine.
Chen, MW; Chen, Y; Cheng, KJ; Jiang, QW; Lv, M; Mei, XL; Qin, WM; Qiu, JG; Shi, Z; Wei, MN; Wei, X; Xue, YQ; Yang, Y; Zhang, WJ; Zhang, X; Zheng, DW, 2015
)
1.01
"Treatment of celastrol not only inhibited adipocyte differentiation (lipid accumulation, glyceraldehyde-3-phosphate dehydrogenase activity and triglyceride content) but also increased lipolysis (glycerol release and free fatty acid release) in 3T3-L1 adipocytes. "( Cascade regulation of PPARγ(2) and C/EBPα signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes.
Cho, HH; Choi, SK; Jang, S; Kim, SH; Lee, S; Moon, HS; Park, S; You, S, 2016
)
1.04
"Pretreatment with celastrol significantly reduced proliferation of PC-3 cells in a dose-dependent manner and cell migration was much slower than in controls. "( Celastrol, an active constituent of the TCM plant Tripterygium wilfordii Hook.f., inhibits prostate cancer bone metastasis.
Huang, S; Kuchta, K; Li, J; Lin, Z; Pan, T; Peng, X; Tang, Y; Wang, X; Xiang, Y; Xu, J; Zhu, Y, 2017
)
2.23
"Treatment with celastrol resulted in a marked increase in antioxidant response element (ARE)-driven transcriptional activity, which was dependent on ROS generation and activation of ERK and p38 MAPK."( Celastrol induces expression of heme oxygenase-1 through ROS/Nrf2/ARE signaling in the HaCaT cells.
Choi, SY; Goh, AR; Ju, SM; Jun, JG; Kim, BC; Kwon, DJ; Park, J; Seo, WY; Song, HY, 2011
)
2.15

Toxicity

Celastrol, triptolide and triptonide have certain toxic effects on liver, kidney, cholangiocyte heart, ear and reproductive system. Despite its narrow range of drug safety in vitro, celastrol was not toxic to the rat spinal cord at 0.

ExcerptReferenceRelevance
" Further acute oral toxicity experiments showed that the LD50 value of this extract was 1,210 mg/kg compared to 257 mg/kg for Tripterygium glycosides."( Biological activity and safety of Tripterygium extract prepared by sodium carbonate extraction.
Fang, W; Lam, CW; Peng, F; Wan, C; Xu, H; Yang, X; Yi, T; Zhang, C, 2012
)
0.38
" However, celastrol, triptolide and triptonide have certain toxic effects on the liver, kidney, cholangiocyte heart, ear and reproductive system."( A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes.
Dai, L; He, GN; Song, J, 2023
)
1.61
"Biotransformation of toxic components by plant endophytes has become an effective method to reduce the toxicity of target compounds and discover lead compounds."( Seven lower toxicity celastrol derivatives by biotransformation of Pestalotiopsis sp. LGT-1.
Ji, H; Jiang, Z; Liu, C; Liu, L; Wang, J; Wu, X; Yue, B; Zhang, S, 2023
)
1.23
" Extensive in vitro and in vivo experiments were performed to investigate both therapeutic efficacy and adverse effects."( A celastrol-based nanodrug with reduced hepatotoxicity for primary and metastatic cancer treatment.
Huang, J; Lai, W; Li, G; Liao, J; Liu, W; Wang, F; Xie, D; Xu, R; Zhang, R; Zhang, Z; Zhou, M, 2023
)
1.63
"Our findings could offer a potential strategy for the translation of toxic compounds into clinical therapeutic nanomedicine."( A celastrol-based nanodrug with reduced hepatotoxicity for primary and metastatic cancer treatment.
Huang, J; Lai, W; Li, G; Liao, J; Liu, W; Wang, F; Xie, D; Xu, R; Zhang, R; Zhang, Z; Zhou, M, 2023
)
1.63

Pharmacokinetics

To establish a sensitive LC-MS/MS method to investigate the pharmacokinetic properties of celastrol in rats.

ExcerptReferenceRelevance
"To establish a sensitive LC-MS/MS method to investigate the pharmacokinetic properties of celastrol in rats."( Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats.
Chu, JH; Ju, WZ; Li, CY; Liu, SJ; Wu, T; Xu, MJ; Zhang, J, 2012
)
0.84
" Main pharmacokinetic parameters including area under the plasma concentration-time curve (AUC), maximal plasma concentration (Cmax), the time for maximal concentration (Tmax) and mean residence time (MRT) were estimated by Drug and Statistic1."( Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats.
Chu, JH; Ju, WZ; Li, CY; Liu, SJ; Wu, T; Xu, MJ; Zhang, J, 2012
)
0.62
" After oral administration of TGV tablets, the Cmax and AUC values of celastrol in female rats were (32."( Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats.
Chu, JH; Ju, WZ; Li, CY; Liu, SJ; Wu, T; Xu, MJ; Zhang, J, 2012
)
0.86
" The results indicated that, when the rats were pretreated with verapamil, the peak concentration of pristimerin increased from 189."( Influence of verapamil on pharmacokinetics of pristimerin in rats.
Gao, X; Liu, S; Wang, Y; Zhang, Y, 2016
)
0.43
" Additionally, in-vivo pharmacokinetic study in healthy rabbits revealed the significantly higher bioavailability of PRT-TRI-PHY compared with TRI-PHY with relative bioavailability of 244%."( Laminated chitosan-based composite sponges for transmucosal delivery of novel protamine-decorated tripterine phytosomes: Ex-vivo mucopenetration and in-vivo pharmacokinetic assessments.
Abdallah, OY; Freag, MS; Saleh, WM, 2018
)
0.48

Compound-Compound Interactions

Celastrol alone or in combination with paclitaxel on survival of anaplastic thyroid carcinoma cells was investigated. Study aimed at exploring the interactive antitumour effects of celastrol combined with tamoxifen.

ExcerptReferenceRelevance
" Inhibitory activity of compounds towards UDP-glucuronosyltransferase (UGT) is an important cause of clinical drug-drug interactions and herb-drug interactions."( Strong inhibition of celastrol towards UDP-glucuronosyl transferase (UGT) 1A6 and 2B7 indicating potential risk of UGT-based herb-drug interaction.
Deng, JP; Gao, XC; Li, G; Ma, RM; Tu, YY; Wang, L; Wang, Q; Yuan, J; Zhang, YS, 2012
)
0.7
" The aim of this study was to investigate the synergistic growth-inhibitive effect of betulinic acid combined with tripterine on MSB-1 cells and its mechanism."( Growth inhibitive effect of betulinic acid combined with tripterine on MSB-1 cells and its mechanism.
An, N; Li, HY; Zhang, XM, 2015
)
0.42
"The influence of celastrol alone or in combination with paclitaxel on survival of anaplastic thyroid carcinoma cells was investigated."( Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ; Yoo, HJ, 2017
)
1.12
" Our study is aimed at exploring the interactive antitumour effects of celastrol combined with tamoxifen and the potential underlying anticancer mechanisms in MCF-7 cells."( The Synergistic Effects of Celastrol in combination with Tamoxifen on Apoptosis and Autophagy in MCF-7 Cells.
Liu, C; Shu, Y; Tang, L; Wang, L; Yao, C, 2021
)
1.15

Bioavailability

Celastrol administered orally in the rat was poorly absorbed into the systemic circulation. The use of liposomes as a carrier of celastrol increased the bioavailability and reduced the side effects of the compound.

ExcerptReferenceRelevance
" In this study, we found that the use of liposomes as a carrier of celastrol increased the bioavailability and reduced the side effects of the compound."( Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol.
Hang, T; Huang, Y; Liu, J; Wang, Z; Wu, Z; Xie, X; Xu, Q; Zhou, D; Zhou, Y; Zuo, J, 2012
)
0.84
"To develop nanostructured-lipid carriers (NLCs) coated with cell-penetrating peptides (CPP) for improving the oral bioavailability of tripterine."( Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine.
Cao, W; Chen, Y; Wu, Q; Yuan, L; Zhang, ZH; Zhou, L, 2012
)
0.38
" In vivo absorption was studied in an in situ rat intestinal perfusion model, and oral bioavailability was examined in beagles."( Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine.
Cao, W; Chen, Y; Wu, Q; Yuan, L; Zhang, ZH; Zhou, L, 2012
)
0.38
" The relative oral bioavailability of the CT-NLCs compared to that of tripterine suspension and T-NLCs were 484."( Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine.
Cao, W; Chen, Y; Wu, Q; Yuan, L; Zhang, ZH; Zhou, L, 2012
)
0.38
"The oral bioavailability of tripterine is dramatically increased by CT-NLCs."( Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine.
Cao, W; Chen, Y; Wu, Q; Yuan, L; Zhang, ZH; Zhou, L, 2012
)
0.38
" The oral absolute bioavailability of celastrol significantly increased from 17."( Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats.
Chu, JH; Ju, WZ; Li, CY; Liu, SJ; Wu, T; Xu, MJ; Zhang, J, 2012
)
0.89
"Celastrol administered orally in the rat was poorly absorbed into the systemic circulation."( Oral bioavailability and gender-related pharmacokinetics of celastrol following administration of pure celastrol and its related tablets in rats.
Chu, JH; Ju, WZ; Li, CY; Liu, SJ; Wu, T; Xu, MJ; Zhang, J, 2012
)
2.06
" Here, we aimed to enhance the oral bioavailability of tripterine (TRI, a plant-derived anticancer compound) using lipid nanospheres (LNs) and to determine the mechanisms of oral absorption."( Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation.
Liu, H; Ma, Z; Sun, H; Wu, B; Zhang, T; Zhang, X; Zhou, X, 2014
)
0.4
"The aims of this study were to choose a suitable adsorbent of self-microemulsion and to develop a fine solid self-microemulsifying dispersible tablets for promoting the dissolution and oral bioavailability of celastrol."( Solid self-microemulsifying dispersible tablets of celastrol: formulation development, charaterization and bioavailability evaluation.
Chou, X; Ma, N; Qi, X; Qin, J; Wu, Z, 2014
)
0.84
" The absolute oral bioavailability of pristimerin is 28."( Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method.
Dong, C; Gao, Y; Liu, H; Peng, J; Xu, C; Xu, S, 2015
)
0.42
" The relative bioavailability of Tri-BLNs and Tri-CLNs was 494."( Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a carrier material.
Li, W; Wu, B; Ye, Y; Zhang, T; Zhang, X, 2015
)
0.42
" Moreover, it suffers from poor bioavailability and off-site toxicity issues."( Exosomal formulation enhances therapeutic response of celastrol against lung cancer.
Agrawal, AK; Aqil, F; Gupta, R; Jeyabalan, J; Kausar, H; Kyakulaga, AH; Munagala, R, 2016
)
0.68
" Additionally, in-vivo pharmacokinetic study in healthy rabbits revealed the significantly higher bioavailability of PRT-TRI-PHY compared with TRI-PHY with relative bioavailability of 244%."( Laminated chitosan-based composite sponges for transmucosal delivery of novel protamine-decorated tripterine phytosomes: Ex-vivo mucopenetration and in-vivo pharmacokinetic assessments.
Abdallah, OY; Freag, MS; Saleh, WM, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The present review examined the chemistry and bioavailability of celastrol and triptolide, and their molecular targets in treating RA."( Therapeutic targets of thunder god vine (Tripterygium wilfordii hook) in rheumatoid arthritis (Review).
Dai, E; Song, X; Zhang, Y, 2020
)
0.8
"As one of the main components of Tripterygium wilfordii Hook F, celastrol (CSL) has significant antitumor activity, but its clinical application has been limited by its poor solubility, low oral bioavailability and systemic toxicity."( Preparation of high drug-loading celastrol nanosuspensions and their anti-breast cancer activities in vitro and in vivo.
Ao, H; Guo, Y; Han, M; Huang, T; Shen, Y; Wang, X; Wang, Y, 2020
)
1.08
" Cytotoxicity assay, pH-responsive release, pain behavior, MRI, safranin o fast green staining, ELISA and western blot analysis were applied to evaluate the bioavailability and therapeutic effect of CSL@HMSNs-Cs."( Intra-articular delivery of celastrol by hollow mesoporous silica nanoparticles for pH-sensitive anti-inflammatory therapy against knee osteoarthritis.
Ji, Y; Jin, T; Jin, YY; Liu, XM; Ma, BJ; Ma, K; Wu, D; Wu, SY; Wu, T; Xu, JT, 2020
)
0.85
" However, due to its poor water solubility, low bioavailability and toxicity, the clinical development and trials of celastrol have been postponed."( Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases.
Bai, X; Chen, YY; Fu, RJ; Tang, YP; Xu, DQ; Yue, SJ; Zhang, S, 2021
)
1.12
" As a promising anti-obesity drug, plant-derived celastrol is challenged by poor water solubility and low oral bioavailability in clinical applications."( Biodegradable celastrol-loaded albumin nanoparticles ameliorate inflammation and lipid accumulation in diet-induced obese mice.
Fan, N; Rong, J; Shen, Y; Shum, HC; Song, Q; Wang, Y; Zhao, J; Zhao, W, 2022
)
1.34
" Cela/GCTR PMs possessed reactive oxygen species (ROS)-responsive properties in vitro and in cells, could improve the bioavailability of Cela, and exert remarkable hepatoma-targeting properties."( Hepatoma-targeting and reactive oxygen species-responsive chitosan-based polymeric micelles for delivery of celastrol.
Lin, Y; Liu, J; Wang, X; Xu, W; Xu, X; Zhang, X; Zheng, Y, 2023
)
1.12
" Subsequently, studies of its toxicity and pharmacokinetic properties showed that celastrol has some adverse effects, low oral bioavailability and a narrow therapeutic window."( Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Dai, S; Fu, K; Gong, L; Li, Y; Ma, C; Peng, C; Wang, C; Zhang, Y; Zhao, X, 2023
)
2.58

Dosage Studied

Celastrol was investigated by administering celastrol intraperitoneally at a dosage of 1 mg/Kg in 35 week-old Tg PS1/APPsw for 4 consecutive days.

ExcerptRelevanceReference
" An acute treatment with celastrol was investigated by administering celastrol intraperitoneally at a dosage of 1 mg/Kg in 35 week-old Tg PS1/APPsw for 4 consecutive days."( Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.
Ait-Ghezala, G; Bachmeier, C; Beaulieu-Abdelahad, D; Ganey, NJ; Laporte, V; March, A; Mullan, MJ; Paris, D; Patel, NS, 2010
)
0.93
" Site-directed drug delivery systems would thus render more effective and safer treatments by increasing local dosage and minimizing toxicity."( Tunable physiologic interactions of adhesion molecules for inflamed cell-selective drug delivery.
Chen, X; Daniel, S; Dickens, G; Jin, MM; Kang, S; Lee, B; Lu, K; Park, T; Rakhilin, N, 2011
)
0.37
" These spherical CST/DOX NPs can improve the water-solubility of CST, reduce the dosage of DOX, and therefore significantly enhance cellular drug accumulation by activating heat shock factor 1 (HSF-1) and inhibiting NF-κB to depress P-gp expression, which results in apoptosis and autophagy of DOX resistant cells through the ROS/JNK signaling pathway."( Synergistic combination chemotherapy using carrier-free celastrol and doxorubicin nanocrystals for overcoming drug resistance.
Chen, C; Guo, M; Jin, J; Liu, J; Liu, Y; Xiao, Y; Zhang, Z; Zhou, H, 2018
)
0.73
" The affected tumors remained dormant long after dosing stopped, resulting in a prolonged progression-free survival and sustained immune surveillance of the host bearing desmoplastic melanoma."( Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.
Chen, F; Hou, L; Huang, L; Liu, Q; Shen, L; Wang, D; Zhang, X, 2018
)
0.48
" Furthermore, celastrol enhanced the growth inhibition and apoptosis induction of cancer cells by sorafenib both in vitro and in vivo and reduced the dosage of sorafenib needed."( Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.
Chen, Z; Kong, LC; Wei, P; Wu, SS; Xu, J; Zhang, R, 2019
)
2.32
" Under the administration of lethal dosage of Celastrol, the tumors are greatly suppressed and the mice maintain the activity."( Self-assembling nanoarchitectonics of size-controllable celastrol nanoparticles for efficient cancer chemotherapy with reduced systemic toxicity.
Li, J; Liu, Y, 2023
)
1.41
" Suitable combination therapy, new dosage forms and new routes of administration can effectively reduce toxicity and increase the effect."( A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes.
Dai, L; He, GN; Song, J, 2023
)
1.21
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
anti-inflammatory drugA substance that reduces or suppresses inflammation.
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitorA topoisomerase inhibitor that inhibits DNA topoisomerase (ATP-hydrolysing), EC 5.99.1.3 (also known as topoisomerase II and as DNA gyrase), which catalyses ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
Hsp90 inhibitorAn EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor that blocks the action of heat shock protein 90.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pentacyclic triterpenoid
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency2.95660.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency0.82890.00529.466132.9993AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.74120.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency1.06650.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency11.98770.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency23.91850.00108.379861.1304AID1645840
polyproteinZika virusPotency2.95660.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency3.61860.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency11.98770.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Telomerase reverse transcriptaseHomo sapiens (human)IC50 (µMol)0.78000.00062.69489.4000AID1201765
Ubiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)IC50 (µMol)31.40005.40006.10006.8000AID1794863
Ubiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)IC50 (µMol)31.40003.00005.06676.8000AID1794863
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)10.30000.00402.92669.9600AID1805801; AID463921
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusKi4.20000.00753.00839.1100AID1805801; AID463922
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)10.30000.00022.45859.9600AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2Ki4.20000.00001.63079.0000AID1805801
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)8.41000.05373.075710.0000AID1754168
Ubiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)IC50 (µMol)31.40000.05003.908310.0000AID1794863
Tyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)IC50 (µMol)20.90000.70004.58049.4500AID1574293; AID1574295
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)6.70000.00053.49849.7600AID1574292; AID1574294; AID551434
Tyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)IC50 (µMol)15.45000.29002.20754.2300AID1574314; AID551433
Tryptophan 2,3-dioxygenaseHomo sapiens (human)IC50 (µMol)100.00000.11001.66929.8000AID1754169
Tyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)IC50 (µMol)3.56670.31804.00429.6000AID1574315; AID1866108; AID551432
Receptor-type tyrosine-protein phosphatase etaHomo sapiens (human)IC50 (µMol)111.50001.00002.00003.0000AID1574317
Hypoxia-inducible factor 1-alphaHomo sapiens (human)IC50 (µMol)0.25000.00072.46529.2100AID1778386
Regulator of G-protein signaling 17Homo sapiens (human)IC50 (µMol)27.93381.38605.936310.0000AID1377215; AID1377218; AID1377220; AID1618223; AID1618224
Ubiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)IC50 (µMol)31.40005.40006.10006.8000AID1794863
Ubiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)IC50 (µMol)31.40005.40006.10006.8000AID1794863
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
L-ornithine N(5)-monooxygenaseAspergillus fumigatus Af293Kd1.40001.40001.40001.4000AID1380060; AID1802216
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)Kd6.08006.08006.08006.0800AID1574303
Nuclear receptor subfamily 4 group A member 1Homo sapiens (human)Kd0.30000.29000.72331.5100AID1597523; AID1597524; AID1808436
Heat shock factor protein 1Homo sapiens (human)EC50 (µMol)1.85001.10001.85002.6000AID428033; AID428034
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (473)

Processvia Protein(s)Taxonomy
telomere maintenanceTelomerase reverse transcriptaseHomo sapiens (human)
RNA-templated transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
RNA-templated DNA biosynthetic processTelomerase reverse transcriptaseHomo sapiens (human)
telomere maintenance via telomeraseTelomerase reverse transcriptaseHomo sapiens (human)
mitochondrion organizationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of gene expressionTelomerase reverse transcriptaseHomo sapiens (human)
DNA strand elongationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of Wnt signaling pathwayTelomerase reverse transcriptaseHomo sapiens (human)
siRNA processingTelomerase reverse transcriptaseHomo sapiens (human)
regulation of protein stabilityTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of hair cycleTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of neuron apoptotic processTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of angiogenesisTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of glucose importTelomerase reverse transcriptaseHomo sapiens (human)
response to cadmium ionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityTelomerase reverse transcriptaseHomo sapiens (human)
establishment of protein localization to telomereTelomerase reverse transcriptaseHomo sapiens (human)
cellular response to hypoxiaTelomerase reverse transcriptaseHomo sapiens (human)
DNA biosynthetic processTelomerase reverse transcriptaseHomo sapiens (human)
replicative senescenceTelomerase reverse transcriptaseHomo sapiens (human)
siRNA transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of miRNA transcriptionTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of transdifferentiationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of protein localization to nucleolusTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of endothelial cell apoptotic processTelomerase reverse transcriptaseHomo sapiens (human)
positive regulation of stem cell proliferationTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of cellular senescenceTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandTelomerase reverse transcriptaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
muscle organ developmentUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
circadian regulation of gene expressionUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
entrainment of circadian clock by photoperiodUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
locomotor rhythmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
positive regulation of mitotic cell cycleUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
circadian behaviorUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein stabilizationUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
male germ cell proliferationUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
response to ischemiaUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
axon target recognitionUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
adult walking behaviorUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
regulation of macroautophagyUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
axonal transport of mitochondrionUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
eating behaviorUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
negative regulation of MAP kinase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
positive regulation of glycolytic processUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
neuromuscular processUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
muscle cell developmentUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cellular response to xenobiotic stimulusUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
protein ubiquitinationUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
post-translational protein modificationUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of lipid storageTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
B cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage differentiationTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of gluconeogenesisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of chemotaxisTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-6-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-2-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of interleukin-4-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of macrophage colony-stimulating factor signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of positive thymic T cell selectionTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
negative regulation of receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 1Homo sapiens (human)
positive regulation of endothelial cell proliferationNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
response to amphetamineNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
cell migration involved in sprouting angiogenesisNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 1Homo sapiens (human)
apoptotic processNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
inflammatory responseNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
signal transductionNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
neurotransmitter secretion involved in regulation of skeletal muscle contractionNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
detection of lipopolysaccharideNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
endothelial cell chemotaxisNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
skeletal muscle cell differentiationNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
positive regulation of apoptotic processNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
cellular response to fibroblast growth factor stimulusNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
fat cell differentiationNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
negative regulation of cell cycleNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 1Homo sapiens (human)
response to electrical stimulusNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
regulation of type B pancreatic cell proliferationNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
non-canonical inflammasome complex assemblyNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 1Homo sapiens (human)
protein dephosphorylationReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of humoral immune response mediated by circulating immunoglobulinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell proliferationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
natural killer cell mediated cytotoxicityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of apoptotic processTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of MAPK cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of B cell differentiationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
platelet aggregationTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
negative regulation of inflammatory response to woundingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
epididymis developmentTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
intracellular signal transductionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
mitotic cell cycleTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
MAPK cascadeTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
tryptophan catabolic process to kynurenineTryptophan 2,3-dioxygenaseHomo sapiens (human)
protein homotetramerizationTryptophan 2,3-dioxygenaseHomo sapiens (human)
response to nitroglycerinTryptophan 2,3-dioxygenaseHomo sapiens (human)
tryptophan catabolic process to acetyl-CoATryptophan 2,3-dioxygenaseHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of protein phosphorylationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
protein dephosphorylationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
apoptotic processPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
spindle assembly involved in female meiosisPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
neuron-neuron synaptic transmissionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
synapse assemblyPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
central nervous system developmentPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
heart developmentPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
learning or memoryPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
locomotory behaviorPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
positive regulation of cell population proliferationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of cell population proliferationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of epithelial to mesenchymal transitionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
regulation of neuron projection developmentPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of neuron projection developmentPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cell migrationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
dentate gyrus developmentPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
central nervous system neuron axonogenesisPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of cell migrationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
adult behaviorPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
regulation of protein stabilityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
central nervous system myelin maintenancePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
multicellular organismal response to stressPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
social behaviorPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
maternal behaviorPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
locomotor rhythmPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of cell sizePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of organ growthPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
phosphatidylinositol dephosphorylationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
forebrain morphogenesisPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of axonogenesisPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
protein stabilizationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of keratinocyte migrationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of focal adhesion assemblyPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
rhythmic synaptic transmissionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
canonical Wnt signaling pathwayPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
synapse maturationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
prepulse inhibitionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
dendritic spine morphogenesisPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cellular response to electrical stimulusPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of excitatory postsynaptic potentialPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
presynaptic membrane assemblyPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
postsynaptic density assemblyPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of cell cycle G1/S phase transitionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of wound healing, spreading of epidermal cellsPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
positive regulation of ubiquitin protein ligase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of G1/S transition of mitotic cell cyclePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of cellular senescencePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
negative regulation of synaptic vesicle clusteringPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cell motilityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHeat shock factor protein 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHeat shock factor protein 1Homo sapiens (human)
MAPK cascadeHeat shock factor protein 1Homo sapiens (human)
DNA repairHeat shock factor protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHeat shock factor protein 1Homo sapiens (human)
mRNA processingHeat shock factor protein 1Homo sapiens (human)
defense responseHeat shock factor protein 1Homo sapiens (human)
response to nutrientHeat shock factor protein 1Homo sapiens (human)
positive regulation of gene expressionHeat shock factor protein 1Homo sapiens (human)
negative regulation of gene expressionHeat shock factor protein 1Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processHeat shock factor protein 1Homo sapiens (human)
response to activityHeat shock factor protein 1Homo sapiens (human)
negative regulation of protein-containing complex assemblyHeat shock factor protein 1Homo sapiens (human)
response to testosteroneHeat shock factor protein 1Homo sapiens (human)
cellular response to heatHeat shock factor protein 1Homo sapiens (human)
cellular response to unfolded proteinHeat shock factor protein 1Homo sapiens (human)
cellular response to potassium ionHeat shock factor protein 1Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinHeat shock factor protein 1Homo sapiens (human)
positive regulation of macrophage differentiationHeat shock factor protein 1Homo sapiens (human)
positive regulation of mitotic cell cycleHeat shock factor protein 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHeat shock factor protein 1Homo sapiens (human)
mRNA transportHeat shock factor protein 1Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHeat shock factor protein 1Homo sapiens (human)
positive regulation of stress granule assemblyHeat shock factor protein 1Homo sapiens (human)
protein-containing complex assemblyHeat shock factor protein 1Homo sapiens (human)
cellular response to hydrogen peroxideHeat shock factor protein 1Homo sapiens (human)
cellular response to lipopolysaccharideHeat shock factor protein 1Homo sapiens (human)
cellular response to cadmium ionHeat shock factor protein 1Homo sapiens (human)
cellular response to copper ionHeat shock factor protein 1Homo sapiens (human)
cellular response to estradiol stimulusHeat shock factor protein 1Homo sapiens (human)
cellular response to xenobiotic stimulusHeat shock factor protein 1Homo sapiens (human)
cellular response to gamma radiationHeat shock factor protein 1Homo sapiens (human)
cellular response to diamideHeat shock factor protein 1Homo sapiens (human)
negative regulation of inclusion body assemblyHeat shock factor protein 1Homo sapiens (human)
positive regulation of inclusion body assemblyHeat shock factor protein 1Homo sapiens (human)
positive regulation of cold-induced thermogenesisHeat shock factor protein 1Homo sapiens (human)
regulation of cellular response to heatHeat shock factor protein 1Homo sapiens (human)
response to peptideHeat shock factor protein 1Homo sapiens (human)
positive regulation of apoptotic DNA fragmentationHeat shock factor protein 1Homo sapiens (human)
cellular response to sodium arseniteHeat shock factor protein 1Homo sapiens (human)
cellular response to angiotensinHeat shock factor protein 1Homo sapiens (human)
cellular response to nitroglycerinHeat shock factor protein 1Homo sapiens (human)
cellular response to L-glutamineHeat shock factor protein 1Homo sapiens (human)
response to hypobaric hypoxiaHeat shock factor protein 1Homo sapiens (human)
response to psychosocial stressHeat shock factor protein 1Homo sapiens (human)
negative regulation of double-strand break repair via nonhomologous end joiningHeat shock factor protein 1Homo sapiens (human)
DNA damage checkpoint signalingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
triglyceride metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
axonogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
brain developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
heart developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cerebellar cortex formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet formationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
T cell costimulationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of chondrocyte differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
microvillus organizationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interferon-beta productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organism growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
organ growthTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
megakaryocyte developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
atrioventricular canal developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
hormone metabolic processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
glucose homeostasisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein-containing complex assemblyTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ossificationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of glucose importTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of insulin secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of protein export from nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
multicellular organismal reproductive processTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
genitalia developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
inner ear developmentTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
homeostasis of number of cells within a tissueTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of cortisol secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
negative regulation of growth hormone secretionTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
face morphogenesisTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
intestinal epithelial cell migrationTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
angiogenesisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
vasculogenesisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
heart developmentReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
blood coagulationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell population proliferationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of platelet activationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of macrophage chemotaxisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
regulation of cell adhesionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet formationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell growthReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of cell migrationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
peptidyl-tyrosine dephosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
glucose homeostasisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of vascular permeabilityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of MAP kinase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of cell adhesionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
oligodendrocyte differentiationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of phagocytosisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of calcium-mediated signalingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
T cell receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of T cell receptor signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive chemotaxisReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of focal adhesion assemblyReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
contact inhibitionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of Fc receptor mediated stimulatory signaling pathwayReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein dephosphorylationReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
positive regulation of chemokine-mediated signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of signaling receptor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to reactive oxygen speciesHypoxia-inducible factor 1-alphaHomo sapiens (human)
angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular glucose homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural crest cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial to mesenchymal transitionHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic placenta developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
B-1 B cell homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of endothelial cell proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
heart loopingHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
chondrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
glandular epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingHypoxia-inducible factor 1-alphaHomo sapiens (human)
outflow tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
cardiac ventricle morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactate metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of glycolytic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular iron ion homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
signal transductionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactationHypoxia-inducible factor 1-alphaHomo sapiens (human)
visual learningHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to iron ionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of epithelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to muscle activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
axonal transport of mitochondrionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural fold elevation formationHypoxia-inducible factor 1-alphaHomo sapiens (human)
cerebral cortex developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular oxygen homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of chemokine productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transforming growth factor beta2 productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
collagen metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to oxidative stressHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic hemopoiesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
hemoglobin biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of erythrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of growthHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
muscle cell cellular homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of hormone biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
digestive tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of nitric-oxide synthase activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuron apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
elastin metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
intestinal epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
iris morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
retina vasculature development in camera-type eyeHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of thymocyte apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to interleukin-1Hypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
dopaminergic neuron differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to virusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of mitophagyHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of aerobic respirationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of protein neddylationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
response to amphetamineRegulator of G-protein signaling 17Homo sapiens (human)
G protein-coupled receptor signaling pathwayRegulator of G-protein signaling 17Homo sapiens (human)
negative regulation of signal transductionRegulator of G-protein signaling 17Homo sapiens (human)
proteolysisUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
BMP signaling pathwayUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
monoubiquitinated protein deubiquitinationUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
transcription elongation-coupled chromatin remodelingUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
positive regulation of RIG-I signaling pathwayUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediatorUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
negative regulation of antifungal innate immune responseUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
protein K27-linked deubiquitinationUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
telomere maintenanceUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of DNA replicationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
DNA repairUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of DNA repairUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
DNA recombinationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
chromatin remodelingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
protein deubiquitinationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
lateral ventricle developmentUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
midbrain developmentUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of chromosome organizationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of DNA repairUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of smoothened signaling pathwayUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of DNA-templated transcriptionUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of embryonic developmentUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
forebrain morphogenesisUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of cell cycleUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of DNA strand elongationUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
regulation of proteasomal protein catabolic processUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
positive regulation of telomere maintenance in response to DNA damageUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (139)

Processvia Protein(s)Taxonomy
tRNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
transcription coactivator bindingTelomerase reverse transcriptaseHomo sapiens (human)
DNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
telomerase activityTelomerase reverse transcriptaseHomo sapiens (human)
telomerase RNA reverse transcriptase activityTelomerase reverse transcriptaseHomo sapiens (human)
RNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
RNA-directed DNA polymerase activityTelomerase reverse transcriptaseHomo sapiens (human)
RNA-dependent RNA polymerase activityTelomerase reverse transcriptaseHomo sapiens (human)
protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
identical protein bindingTelomerase reverse transcriptaseHomo sapiens (human)
protein homodimerization activityTelomerase reverse transcriptaseHomo sapiens (human)
metal ion bindingTelomerase reverse transcriptaseHomo sapiens (human)
protein-folding chaperone bindingTelomerase reverse transcriptaseHomo sapiens (human)
telomerase RNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
template-free RNA nucleotidyltransferaseTelomerase reverse transcriptaseHomo sapiens (human)
telomeric DNA bindingTelomerase reverse transcriptaseHomo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cyclin bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
ubiquitin protein ligase bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
identical protein bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
metal ion bindingUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
omega peptidase activityUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
ubiquitin protein ligase bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
alpha-2A adrenergic receptor bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
ubiquitin bindingUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
peptidase activityUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
deNEDDylase activityUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
ubiquitin bindingUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
integrin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
syntaxin bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
STAT family protein bindingTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
lipopolysaccharide bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
DNA bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
protein bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
identical protein bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
protein heterodimerization activityNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
transmembrane receptor protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
SH2 domain bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
tryptophan 2,3-dioxygenase activityTryptophan 2,3-dioxygenaseHomo sapiens (human)
protein bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
amino acid bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
oxygen bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
heme bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
identical protein bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
metal ion bindingTryptophan 2,3-dioxygenaseHomo sapiens (human)
phosphatidylinositol-3-phosphate phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
phosphoprotein phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
protein serine/threonine phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
protein tyrosine phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
protein bindingPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
lipid bindingPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
anaphase-promoting complex bindingPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
myosin phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
enzyme bindingPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
PDZ domain bindingPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
identical protein bindingPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
phosphatidylinositol-3,4-bisphosphate 3-phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
phosphatidylinositol phosphate phosphatase activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
ubiquitin-specific protease bindingPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
ubiquitin ligase activator activityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
transcription cis-regulatory region bindingHeat shock factor protein 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHeat shock factor protein 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHeat shock factor protein 1Homo sapiens (human)
RNA polymerase II intronic transcription regulatory region sequence-specific DNA bindingHeat shock factor protein 1Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificHeat shock factor protein 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHeat shock factor protein 1Homo sapiens (human)
DNA bindingHeat shock factor protein 1Homo sapiens (human)
protein bindingHeat shock factor protein 1Homo sapiens (human)
protein kinase bindingHeat shock factor protein 1Homo sapiens (human)
heat shock protein bindingHeat shock factor protein 1Homo sapiens (human)
chromatin DNA bindingHeat shock factor protein 1Homo sapiens (human)
identical protein bindingHeat shock factor protein 1Homo sapiens (human)
sequence-specific DNA bindingHeat shock factor protein 1Homo sapiens (human)
protein heterodimerization activityHeat shock factor protein 1Homo sapiens (human)
Hsp90 protein bindingHeat shock factor protein 1Homo sapiens (human)
translation elongation factor bindingHeat shock factor protein 1Homo sapiens (human)
STAT family protein bindingHeat shock factor protein 1Homo sapiens (human)
sequence-specific single stranded DNA bindingHeat shock factor protein 1Homo sapiens (human)
general transcription initiation factor bindingHeat shock factor protein 1Homo sapiens (human)
sequence-specific double-stranded DNA bindingHeat shock factor protein 1Homo sapiens (human)
promoter-specific chromatin bindingHeat shock factor protein 1Homo sapiens (human)
DNA-binding transcription factor activityHeat shock factor protein 1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
signaling receptor complex adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cell adhesion molecule bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
molecular adaptor activityTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein tyrosine phosphatase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
platelet-derived growth factor receptor bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
beta-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
phosphatase activityReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
protein kinase bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
gamma-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cadherin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
mitogen-activated protein kinase bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
delta-catenin bindingReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription repressor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
p53 bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear receptor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
enzyme bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein kinase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein domain specific bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
histone deacetylase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein heterodimerization activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
Hsp90 protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
E-box bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription regulator activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
GTPase activityRegulator of G-protein signaling 17Homo sapiens (human)
GTPase activator activityRegulator of G-protein signaling 17Homo sapiens (human)
protein bindingRegulator of G-protein signaling 17Homo sapiens (human)
cysteine-type endopeptidase activityUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
transforming growth factor beta receptor bindingUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
identical protein bindingUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
SMAD bindingUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
ubiquitin-modified histone reader activityUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
K48-linked deubiquitinase activityUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
RNA bindingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cysteine-type deubiquitinase activityUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
endopeptidase inhibitor activityUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
protein bindingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
proteasome bindingUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (84)

Processvia Protein(s)Taxonomy
PML bodyTelomerase reverse transcriptaseHomo sapiens (human)
chromosome, telomeric regionTelomerase reverse transcriptaseHomo sapiens (human)
nucleusTelomerase reverse transcriptaseHomo sapiens (human)
nucleoplasmTelomerase reverse transcriptaseHomo sapiens (human)
telomerase holoenzyme complexTelomerase reverse transcriptaseHomo sapiens (human)
nucleolusTelomerase reverse transcriptaseHomo sapiens (human)
cytosolTelomerase reverse transcriptaseHomo sapiens (human)
plasma membraneTelomerase reverse transcriptaseHomo sapiens (human)
nuclear speckTelomerase reverse transcriptaseHomo sapiens (human)
mitochondrial nucleoidTelomerase reverse transcriptaseHomo sapiens (human)
TERT-RMRP complexTelomerase reverse transcriptaseHomo sapiens (human)
telomerase catalytic core complexTelomerase reverse transcriptaseHomo sapiens (human)
nuclear telomere cap complexTelomerase reverse transcriptaseHomo sapiens (human)
RNA-directed RNA polymerase complexTelomerase reverse transcriptaseHomo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
centrosomeUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
membraneUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
perinuclear region of cytoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase 2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
endoplasmic reticulum membraneUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
neuronal cell bodyUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
neuron projection terminusUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
axon cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L1Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L3Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 2Homo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
mitochondrionNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
cytosolNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
nuclear membraneNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
presynapseNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
chromatinNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 1Homo sapiens (human)
nucleusReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
cytoplasmReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
plasma membraneReceptor-type tyrosine-protein phosphatase epsilonHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular regionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleolusTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cell-cell junctionTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
membraneTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
specific granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
extracellular exosomeTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
tertiary granule lumenTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
alpha-beta T cell receptor complexTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 6Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
microtubule cytoskeletonTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
mitotic spindleTyrosine-protein phosphatase non-receptor type 7Homo sapiens (human)
cytosolTryptophan 2,3-dioxygenaseHomo sapiens (human)
neuron projectionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
extracellular regionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
nucleusPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
nucleoplasmPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cytoplasmPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cytosolPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
plasma membranePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cytoplasmic side of plasma membranePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
postsynaptic densityPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
apical plasma membranePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
PML bodyPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
myelin sheath adaxonal regionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cell projectionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
dendritic spinePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
Schmidt-Lanterman incisurePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cytosolPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
plasma membranePhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
cell projectionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
nucleusPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENHomo sapiens (human)
kinetochoreHeat shock factor protein 1Homo sapiens (human)
nucleusHeat shock factor protein 1Homo sapiens (human)
nucleoplasmHeat shock factor protein 1Homo sapiens (human)
cytoplasmHeat shock factor protein 1Homo sapiens (human)
centrosomeHeat shock factor protein 1Homo sapiens (human)
cytosolHeat shock factor protein 1Homo sapiens (human)
PML bodyHeat shock factor protein 1Homo sapiens (human)
perinuclear region of cytoplasmHeat shock factor protein 1Homo sapiens (human)
nuclear stress granuleHeat shock factor protein 1Homo sapiens (human)
mitotic spindle poleHeat shock factor protein 1Homo sapiens (human)
chromatinHeat shock factor protein 1Homo sapiens (human)
euchromatinHeat shock factor protein 1Homo sapiens (human)
heterochromatinHeat shock factor protein 1Homo sapiens (human)
protein folding chaperone complexHeat shock factor protein 1Homo sapiens (human)
ribonucleoprotein complexHeat shock factor protein 1Homo sapiens (human)
nucleusHeat shock factor protein 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 11Homo sapiens (human)
immunological synapseReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
plasma membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cell-cell junctionReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
cell surfaceReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
ruffle membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
specific granule membraneReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
extracellular exosomeReceptor-type tyrosine-protein phosphatase etaHomo sapiens (human)
nucleusHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear bodyHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear speckHypoxia-inducible factor 1-alphaHomo sapiens (human)
motile ciliumHypoxia-inducible factor 1-alphaHomo sapiens (human)
axon cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
chromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
euchromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein-containing complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusRegulator of G-protein signaling 17Homo sapiens (human)
cytoplasmRegulator of G-protein signaling 17Homo sapiens (human)
plasma membraneRegulator of G-protein signaling 17Homo sapiens (human)
neuron projectionRegulator of G-protein signaling 17Homo sapiens (human)
synapseRegulator of G-protein signaling 17Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
mitochondrionUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
nuclear bodyUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase 15Homo sapiens (human)
Ino80 complexUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
nucleusUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
nucleoplasmUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
nucleolusUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cytosolUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cytosolic proteasome complexUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
cytoplasmUbiquitin carboxyl-terminal hydrolase isozyme L5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (546)

Assay IDTitleYearJournalArticle
AID1574319Inhibition of mouse LMPTP-B (1 to 158 residues) expressed in Escherichia coli strain BL21(DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1574299Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 336 residues) expressed in Escherichia coli strain Rosetta2 (DE3) up to 500 uM using pNPP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mi2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1821527Antimigratory activity against human U-251 cells assessed as inhibition of cell migration measured upto 24 hrs by wound healing assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID567643Displacement of geldanamycin bound sepharose from HSP90 after 5 mins by affinity chromatography analysis2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1495988Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Lactones from the pericarps of Litsea japonica and their anti-inflammatory activities.
AID332899Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID684933Antiarthritic effect in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in MCP1 production pre-incubated with compound for 30 mins before stimulation with sonicated-Mtb for 48 h2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1581353Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID222466Compound was tested for inhibitory effect on LPS-stimulated IL-6 release from human monocytes1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine.
AID1454157Cytotoxic activity against human A549 cells incubated for 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1808299Modulation of Gal4-fused VP16 expressed in PC12 cells co-transfected with UAS repoter gene assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1377225Inhibition of Galpha0 interaction with GFP-fused RGS17 (unknown origin) deltaN mutant expressed in HEK293 cells assessed as increase in RGS17 deltaN mutant localization at cytoplasm at 100 uM up to 5 mins by confocal microscopic analysis2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1675572Selectivity index, ratio of CC50 for cytotoxicity against BALB/c mouse T cell to IC50 for antiproliferative activity against Con A-induced BALB/c mouse T cell2020Journal of natural products, 09-25, Volume: 83, Issue:9
Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents.
AID1501729Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.
AID1597522Binding affinity to GFP-Nur77 (unknown origin) expressed in human HepG2 cells cotransfected with mCherry-p62/SQSTM1 assessed as co-localization with p62/SQSTM1 in cytoplasm in presence of TNFalpha by DAPI staining based confocal microscopic analysis2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID332908Cytotoxicity against human LNCAP cells after 72 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID1225605Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID636747Cytotoxicity against human NCI-H460 cells after overnight incubation by MTT assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Diarylheptanoids from the seeds of Alpinia katsumadai as heat shock factor 1 inducers.
AID391883Inhibition of TNF-alpha-induced NF-kappaB activation in human HeLa cells by SEAP reporter gene assay2008Journal of natural products, Oct, Volume: 71, Issue:10
Phenolic constituents of Amorpha fruticosa that inhibit NF-kappaB activation and related gene expression.
AID1574295Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 296 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluor2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1377215Inhibition of RGS17 (unknown origin) GAP activity in presence of GTP by malachite green dye based assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID222458Inhibition of IL1-beta release stimulated with LPS in human monocytes1999Bioorganic & medicinal chemistry letters, Feb-08, Volume: 9, Issue:3
Novel cytokine release inhibitors. Part IV: analogs of podocarpic acid.
AID428038Cytoprotection against rotenone stress-induced toxicity in human SK-N-SH cells at 0.16 uM after 48 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID332196Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production treated 3 hrs before LPS challenge assessed after 24 hrs by Griess reagent assay2002Journal of natural products, Jan, Volume: 65, Issue:1
Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production.
AID567629Inhibition of HSP90 binding to Cdc37 in human SKBR-3 cells by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1377862Selectivity index, ratio of IC50 for human BJ cells to IC50 for human A549 cells2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID1879840Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
AID222464Compound was tested for inhibitory effect on LPS-stimulated IL-1 alpha release from human monocytes1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine.
AID1377232Induction of morphological changes in HEK293 cells assessed as plasma membrane blebbing at 100 uM2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID485531Inhibition of NF-kappaB activity in human HeLa cells by SEAP reporter assay2010Journal of natural products, Jun-25, Volume: 73, Issue:6
An isoaurone and other constituents from Trichosanthes kirilowii seeds inhibit hypoxia-inducible factor-1 and nuclear factor-kappaB.
AID1574308Inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 393 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins in prese2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1574303Binding affinity to human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) by switch sense technology based assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1556979Antiproliferative activity against human OVCAR3 cells incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents.
AID1377217Solubility of the compound in aqueous buffer solution2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1506871Antiproliferative activity against human SKBR3 cells at 10 uM after 72 hrs by MTT assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1596417Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1778387Cytotoxicity against human Hep3B cells assessed as reduction in cell viability incubated for 24 hrs under normaxic condition by MTT assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway.
AID1854212Reduction of RNA surrogate poly(I:C)-induced IFN release in mouse RAW-Lucia ISG cells2022European journal of medicinal chemistry, Aug-05, Volume: 238Small molecules targeting cGAS-STING pathway for autoimmune disease.
AID684927Antiarthritic effect in Lewis rat adjuvant-induced arthritis model synovial infiltrating cells restimulated with sonicated Mtb post isolation assessed as reduction in RANTES production at 200 ug, ip starting from arthritis onset and continued uninterrupte2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1879836Selectivity index, ratio of IC50 for antiproliferative activity against human L02 cells assessed as inhibition of cell growth to IC50 for antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth2022European journal of medicinal chemistry, Apr-15, Volume: 234Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
AID1225610Change in Cdc37 expression in human MCF7 cells at 5 times IC50 after 24 hrs by Western blot analysis2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1808340Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with luciferase reporter plasmid harboring NurRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene assa2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1597529Induction of apoptosis in TNFalpha-treated human HepG2 cells assessed as viable apoptotic cells at 2 uM incubated for 10 hrs by FITC Annexin V and propidium iodide staining based flow cytometric analysis (Rvb = 3.69%)2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID567631Modulation proteolytic fingerprint of HSP90 in rabbit reticulocyte lysates at 20 uM after 5 mins by SDS-PAGE analysis in presence of 125 ug/ml of trypsin2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID685078Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in CXCR2 expression at 200 ug, ip starting from arthritis onset and continued uninterrupted until2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1808301Modulation of Gal4-fused VP16 expressed in HEK293T cells co-transfected with UAS repoter gene assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1903924Antiproliferative activity against human A549 cells expressing Hsp90 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
AID1597525Antiinflammatory activity in human HepG2 cells assessed as inhibition of TNFalpha-induced IkappaBalpha degradation at 2 uM pretreated for 1 hr followed by TNFalpha addition and measured after 30 mins by Western blot analysis2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID1377861Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID1597523Binding affinity to recombinant human N-terminal His-tagged Nur77 LBD (367 to 598 residues) expressed in Escherichia coli BL21(DE3) incubated for 30 secs by fluorescence quenching assay2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID684936Antiarthritic effect in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in TNFalpha production pre-incubated with compound for 30 mins before stimulation with sonicated-Mtb for 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID684924Antiarthritic effect in Lewis rat adjuvant-induced arthritis model lymph node cells restimulated with sonicated Mtb post isolation assessed as reduction in MIP-1alpha production at 200 ug, ip starting from arthritis onset and continued uninterrupted until2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1903923Antiproliferative activity against human A549 cells expressing Hsp90-Cdc37 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
AID685079Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in CXCR4 expression at 200 ug, ip starting from arthritis onset and continued uninterrupted until2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1808336Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with luciferase reporter plasmid harboring NurRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene 2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID391884Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells by SEAP reporter gene assay2008Journal of natural products, Oct, Volume: 71, Issue:10
Phenolic constituents of Amorpha fruticosa that inhibit NF-kappaB activation and related gene expression.
AID1506877Effect on HSP90 level in human SKBR3 cells at 1 to 50 uM after 24 hrs by Western blot analysis2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1322011Inhibition of His-tagged full length Hsp90/GST-tagged Cdc37 middle domain (unknown origin) interaction after 1 hr by TR-FRET assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
AID1225614Inhibition of HSP90 in human MCF7 cells assessed as induction of heat shock response-mediated HSP27 production at 5 times IC50 after 24 hrs by Western blot analysis relative to vehicle-treated control2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1783336Induction of apoptosis in human HePAD38 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.158%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID356588Cytotoxicity against human KBVIN cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID684682Increase in CCR1 protein surface expression in sonicated Mtb-stimulated spleen adherent cells isolated Inhibition of cell migration of RANTES-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model at 0. 3 uM by Transwell2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1604464Antitumor activity against human PANC1 cells xenografted in athymic mouse at 3 mg/kg, ip administered for 2 continuous days followed by 1 injection per 3 days and measured twice per week relative to control2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
AID684931Antiarthritic effect in Lewis rat adjuvant-induced arthritis model synovial infiltrating cells restimulated with sonicated Mtb post isolation assessed as reduction in MIP-1alpha production at 200 ug, ip starting from arthritis onset and continued uninterr2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1377222Binding affinity to RGS17 (unknown origin) assessed as covalent adduct formation at 100 uM after 72 hrs by ESI-MS analysis2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1783328Induction of apoptosis in human L02 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 1.49%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID567628Inhibition of HSP90 in human MCF7 cells assessed as degradation of AKT protein after 48 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID718435Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Compounds from the heartwood of Caesalpinia sappan and their anti-inflammatory activity.
AID356587Cytotoxicity against human KB cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID356594Cytotoxicity against human 1A9/PTX10 cells after 6 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID684945Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in CCR5 expression at 200 ug, ip starting from arthritis onset and continued uninterrupted until 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID527506Induction of apoptosis in TRAIL-resistant human THP1 cells assessed as pro-apoptotic cells at 50 uM after 24 hrs by annexin-V staining2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis of exotic polycycles such as cyclooctatrienes and fenestrenes with differential pro-apoptotic activities on human TRAIL-resistant metastatic cell lines.
AID684918Antiarthritic effect in Lewis rat adjuvant-induced arthritis model lymph node cells restimulated with sonicated Mtb post isolation assessed as reduction in GRO/KC production at 200 ug, ip starting from arthritis onset and continued uninterrupted until stu2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID401067Cytotoxicity against human HT-29 cells after 72 hrs by Alamar blue assay1998Journal of natural products, Jun-26, Volume: 61, Issue:6
Novel quinone methides from Salacia kraussii with in vitro antimalarial activity.
AID1866622Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 0.5 uM incubated for 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.11%)
AID1377220Inhibition of RGS17 (unknown origin) C117A mutant interaction with biotinylated Galphao after 30 mins in presence of AMF and GDP by AlphaScreen assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1808325Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NBRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase re2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID684922Antiarthritic effect in Lewis rat adjuvant-induced arthritis model lymph node cells restimulated with sonicated Mtb post isolation assessed as reduction in IL-1beta production at 200 ug, ip starting from arthritis onset and continued uninterrupted until s2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1501727Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.
AID428045Cytoprotection against oxygen-glucose deprivation-induced cytotoxicity in human SH-SY5Y cells at 1 uM after 28 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID489309Cytoprotective activity against t-BPH-induced cell damage in rat PC12 cells assessed as cell viability2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells.
AID1808333Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NBRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase rep2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1501726Antiproliferative activity against human BJ cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.
AID428044Cytoprotection against oxygen-glucose deprivation-induced cytotoxicity in human SH-SY5Y cells at 0.5 uM after 28 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID1596419Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1854213Inhibition of human telomeric DNA transfected in human THP-1 cells by measuring luciferase signal2022European journal of medicinal chemistry, Aug-05, Volume: 238Small molecules targeting cGAS-STING pathway for autoimmune disease.
AID1506875Inhibition of HSP90/Cdc37 protein-protein interaction in human SKBR3 cells assessed as decrease in Akt level after 24 hrs by Western blot analysis2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1574307Non-competitive inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 393 residues) expressed in Escherichia coli strain Rosetta2 (DE3) at 500 uM in presence of 4'-aminoxanilic acid by STD-NMR spectroscopic method2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1377218Inhibition of wild type GST-tagged RGS17 (unknown origin) interaction with biotinylated Galphao after 30 mins in presence of AMF and GDP by AlphaScreen assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID606873Inhibition of Hsp70 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Hsp70 at 100 uM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1783337Induction of apoptosis in human HePAD38cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.032%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1225608Inhibition of HSP90 in human MCF7 cells assessed as Cdk6 degradation at 5 times IC50 after 24 hrs by Western blot analysis2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1574305Binding affinity to human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) assessed as dissociation rate constant using DiFMUP as substrate preincubated for 10 mins followed by substrate2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1574317Inhibition of human PTPRJ (1019 to 1311 residues) expressed in Escherichia coli strain BL21(DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1808343Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with luciferase reporter plasmid harboring NurRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene a2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1783338Induction of apoptosis in human HePAD38 cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.903%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID463921Inhibition of 3C-like protease of SARS coronavirus assessed as concentration of FRET peptide for 60 mins2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.
AID356584Cytotoxicity against human A549 cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID1868735Antiproliferative activity against human BGC-823 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
AID222465Compound was tested for inhibitory effect on LPS-stimulated IL-1 beta release from human monocytes1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine.
AID1529757Induction of apoptosis in human A549 cells assessed as viable cells at 1.2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 98.5%)
AID1808298Modulation of Gal4-fused VP16 expressed in SKNBE(2) cells co-transfected with UAS repoter gene assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 hrs by luciferase reporter gene assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID674393Cytotoxicity against mouse RAW264.7 cells after 18 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Myxobacteria versus sponge-derived alkaloids: the bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/ELSD libraries.
AID1389864Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
AID1783325Inhibition of human SERCA in human HeLa cells assessed as depletion of SERCA-dependent calcium storage at 1 uM preincubated with TG by FLIPR calcium assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1574320Inhibition of human PTEN (1 to 403 residues) expressed in Escherichia coli strain BL21(DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1556980Antiproliferative activity against human A2780 cells incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents.
AID428033Amplification of HSF1 transcriptional activity in human HeLa cells assessed as granule formation pretreated for 3 hrs by immunocytochemical staining2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID684921Antiarthritic effect in Lewis rat adjuvant-induced arthritis model lymph node cells restimulated with sonicated Mtb post isolation assessed as reduction in TNFalpha production at 200 ug, ip starting from arthritis onset and continued uninterrupted until s2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1574298Inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 393 residues) expressed in Escherichia coli strain Rosetta2 (DE3) up to 500 uM using pNPP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mi2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1783330Induction of apoptosis in human L02 cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.848%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1808339Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with luciferase reporter plasmid harboring NurRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene assa2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1866625Selectivity index, ratio of IC50 for human MRC5 cells to IC50 for human A549 cells
AID1322015Antiproliferative activity against paclitaxel-resistant human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
AID684923Antiarthritic effect in Lewis rat adjuvant-induced arthritis model lymph node cells restimulated with sonicated Mtb post isolation assessed as reduction in IL6 production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1506870Antiproliferative activity against human MCF7 cells at 10 uM after 72 hrs by MTT assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1783317Antiproliferative activity against human HePAD38 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID684934Antiarthritic effect in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in MIP-1alpha production pre-incubated with compound for 30 mins before stimulation with sonicated-Mtb fo2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1866628Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation at 0.125 to 2 uM by MTT assay
AID489315Antitumor activity against human LNCAP cells2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells.
AID684938Antiarthritic effect in IL-1beta-stimulatedspleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in GRO/KC production pre-incubated with compound for 30 mins before stimulation with IL-1beta for 48 hrs by mul2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID332904Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID1866623Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
AID1868738Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
AID1506874Inhibition of N-terminal GST-tagged HSP90/Cdc37 (unknown origin) interaction expressed in Escherichia coli at 20 uM preincubated with Cdc37 for 1 hr followed by addition to HSP90 by GST-pull down assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1821523Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID1377239Growth inhibition of E-cadherin expressing human PC3 cells transfected with RGS17 at 31.6 to 56.2 uM after 1 hr by sulforhodamine B assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1597530Induction of apoptosis in TNFalpha-treated human HepG2 cells assessed as necrotic cells at 2 uM incubated for 10 hrs by FITC Annexin V and propidium iodide staining based flow cytometric analysis (Rvb = 1.29%)2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID1377864Selectivity index, ratio of IC50 for human BJ cells to IC50 for human SKOV3 cells2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID1454158Cytotoxic activity against human Bel7402 cells incubated for 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1529750Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
AID1529760Induction of apoptosis in human A549 cells assessed as necrotic cells at 1.2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.6%)
AID593620Cytotoxicity against human 293T cells assessed as cell viability by dual-luciferase reporter assay2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis of rabdokunmin C analogues and their inhibitory effect on NF-κB activation.
AID1377856Cytotoxicity against human BJ cells assessed as reduction in cell viability after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID1201766Octanol-water partition coefficient, log P of the compound by shake-flask method2015European journal of medicinal chemistry, May-05, Volume: 95Design and synthesis of celastrol derivatives as anticancer agents.
AID1821534Induction of apoptosis in human U-251 cells assessed as nuclear fragmentation at 0.5 to 2 uM measured after 48 hrs by Hoechst 33342 staining based confocal fluorescence microscopic analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID222467Compound was tested for inhibitory effect on LPS-stimulated IL-8 release from human monocytes1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine.
AID356586Cytotoxicity against human HCT8 cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID1873234Toxicity in po dosed mouse assessed as lethal dose2022European journal of medicinal chemistry, Jul-05, Volume: 237Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
AID567639Antiproliferative activity against human LNCAP cells2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1556981Antiproliferative activity against human IOSE-80 cells incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents.
AID1529782Inhibition of HSP90 in human A549 cells assessed as decrease in Akt phosphorylation at 2.5 uM after 24 hrs by Western blot analysis
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1389861Antiproliferative activity against human A549 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
AID222468Compound was tested for inhibitory effect on LPS-stimulated PGE-2 release from human monocytes1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine.
AID1808327Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NurRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase repor2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1866620Induction of apoptosis in human A549 cells assessed as necrotic cells at 0.5 uM incubated for 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3.36%)
AID1574304Binding affinity to human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) assessed as association rate constant using DiFMUP as substrate preincubated for 10 mins followed by substrate 2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1201761Anticancer activity against human SGC7901 cells assessed as cell survival after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design and synthesis of celastrol derivatives as anticancer agents.
AID1891409Inhibition of SARS-CoV-2 main protease expressed in Escherichia coli using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 peptide as substrate at 100 uM incubated for 30 mins by FRET based assay relative to control
AID489307Cytoprotective activity against t-BPH-induced cell damage in rat PC12 cells assessed as cell viability at 0.1 uM2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells.
AID1808344Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with luciferase reporter plasmid harboring NurRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene a2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1574323Antiobesity activity in high fat diet-induced obese Ptpn1fl/fl null C57BL/6 mouse treated with rAAV-CMV-Cre-GFP for deletion of PTP1B and TCPTP assessed as reduction in body weight at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1377221Thiol reactivity of the compound assessed as cysteine adduct formation at 100 uM after 4 hrs in presence of N-Acetylcysteine by Ellman's method2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1597527Induction of apoptosis in TNFalpha-treated human HepG2 cells assessed as PARP cleavage at 2 uM incubated for 10 hrs by Western blot analysis2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID606947Inhibition of Hsp90-mediated [35S]His-tagged HRI maturation in heme-deficient reticulocyte lysate at 100 uM after 45 mins by SDS-PAGE and autoradiography2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID718315Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production incubated for 24 hrs by ELISA2012Journal of natural products, Dec-28, Volume: 75, Issue:12
Phenolic compounds from Caesalpinia sappan heartwood and their anti-inflammatory activity.
AID1808331Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NurRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase re2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID593619Cytotoxicity against mouse RAW264 cells after 2 hrs by WST reagent-based microplate reader analysis2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis of rabdokunmin C analogues and their inhibitory effect on NF-κB activation.
AID593618Inhibition of LPS-induced NO production in mouse RAW264 cells after 24 hrs2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis of rabdokunmin C analogues and their inhibitory effect on NF-κB activation.
AID1574293Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 336 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluor2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID489308Cytoprotective activity against t-BPH-induced cell damage in rat PC12 cells assessed as cell viability at 0.8 uM2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells.
AID1808330Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NBRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase report2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1389860Inhibition of His-tagged full-length Hsp90 (unknown origin)/GST-tagged Cdc37M (unknown origin) interaction after 1 hr by HTRF assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
AID1903909Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
AID1377223Binding affinity to RGS17 (unknown origin) assessed as change in chemical shift perturbations by NMR spectroscopic analysis2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1574292Inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 393 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluor2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1389863Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
AID1741446Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.
AID1501730Antiproliferative activity against human MDA-MB-231cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.
AID1597537Toxicity in zebrafish embryo AB assessed as induction of malformation at 0.5 to 1.25 uM incubated for 24 to 72 hrs2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID1581350Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 1.5 uM incubated for 48 hrs by MTT assay relative to control2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID332903Cytotoxicity against human SK-MEL-2 cells after 72 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID222462Inhibitory activity against LPS-stimulated IL-1 beta release from human monocytes1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine.
AID1201764Anticancer activity against human HepG2 cells assessed as cell survival after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design and synthesis of celastrol derivatives as anticancer agents.
AID1225612Inhibition of HSP90 in human MCF7 cells assessed as induction of heat shock response-mediated HSP90 production at 5 times IC50 after 24 hrs by Western blot analysis relative to vehicle-treated control2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1454172Antitumor activity against human A549 cells xenografted in nude mouse assessed as relative tumor volume at 12 mg/kg, ig dosed every day relative to initial tumor volume2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1783335Induction of apoptosis in human HePAD38 cells assessed as viable cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 98.9%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID684687Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in IL-1beta production at 200 ug, ip starting from arthritis onset and continued uninterrupted un2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1501724Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.
AID1866642Induction of apoptosis in human A549 cells assessed as viable cells at 0.5 uM incubated for 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 95.7%)
AID1574310Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 336 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins in prese2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID428039Cytoprotection against rotenone stress-induced toxicity in human SK-N-SH cells assessed as increase in cell viability after 48 hrs by MTS assay relative to control2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID1783321Selectivity index, ratio of IC50 for human CCD 19Lu cells to IC50 for human HepG2 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1741444Antiproliferative activity against human QGY-7703 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.
AID1574326Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 336 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins in prese2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1529751Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
AID1377236Growth inhibition of human TEM4-18 cells after 1 hr by sulforhodamine B assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1783324Inhibition of human SERCA in human HeLa cells assessed as alteration of calcium dynamics at 1 uM measured by FLIPR calcium assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1380062Antifungal activity against Aspergillus fumigatus ATCC 46645 after 24 hrs2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID1322014Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
AID1454162Toxicity in ip dosed nude mouse assessed as induction of mouse fatality2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID551433Inhibition of recombinant SHP12011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.
AID1506872Antiproliferative activity against human A549 cells at 10 uM after 72 hrs by MTT assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID636745Induction of HSP27 expression in human NCI-H460 cells at 1 uM after 24 hrs by Western blotting relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Diarylheptanoids from the seeds of Alpinia katsumadai as heat shock factor 1 inducers.
AID1574325Inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 393 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins in prese2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1808338Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with luciferase reporter plasmid harboring NBRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene a2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1574294Inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluor2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1868762Induction of apoptosis in human BGC-823 cells assessed as necrotic cells at 1 uM incubated for 24 hrs by annexin-V-FITC and PI staining based flow cytometry analysis (Rvb = 0.6%)
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1755693Inhibition of Salmonella typhimurium LsrK expressed in Escherichia coli MET1158 incubated for 30 mins followed by DPD and ATP addition and measured after 15 mins by kinase-glo max luminescent assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Tackling Antimicrobial Resistance with Small Molecules Targeting LsrK: Challenges and Opportunities.
AID428042Cytotoxicity against human SK-N-SH cells after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID606874Inhibition of Cdc37 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Cdc37 at 100 uM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1783326Inhibition of human SERCA in human HeLa cells assessed as alteration of calcium dynamics at 1 uM preincubated with compound C measured after 2 hrs by FLIPR calcium assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1581354Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID1574297Non competitive inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 336 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1574322Antiobesity activity in high fat diet-induced obese Ptpn1fl/fl null C57BL/6 mouse treated with rAAV-CMV-Cre-GFP for deletion of TCPTP assessed as reduction in body weight at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID685081Increase in CCR1 expression in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model pre-incubated with compound before stimulation with sonicated Mtb for 24 hrs by qPCR2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1596471Induction of apoptosis in human A549 cells assessed as necrotic cells at 2 uM incubated for 24 hrs by AnnexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 3.6%)
AID1808326Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NBRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase re2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1574296Non competitive inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 393 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1574286Antiobesity activity in high fat diet-induced obese Ptpn1fl/fl null C57BL/6 mouse assessed as reduction in body weight at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1808290Cytotoxicity against rat PC12 cells assessed as reduction in cell viability at 1.56 to 6.25 microM incubated for 18 hrs by Cell titer-glo assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1506860Inhibition of full length His-tagged HSP90/GST-tagged Cdc37 (unknown origin) interaction at 10 uM after 1 hr by HTRF assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1868775Antitumor activity against human BGC-823 cells xenografted in athymic BALB/c nude mouse assessed as tumor growth inhibition rate at 1.5 mg/kg, ip measured every 2 days for 21 days by curson caliper method relative to control
AID593621Inhibition of LPS-induced NF-kappaB activation in human 293T cells incubated for 30 mins followed by treated with LPS for 6 hrs by dual-luciferase reporter assay2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Synthesis of rabdokunmin C analogues and their inhibitory effect on NF-κB activation.
AID1581351Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID551434Inhibition of recombinant PTP1B2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.
AID1201763Anticancer activity against human MGC803 cells assessed as cell survival after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design and synthesis of celastrol derivatives as anticancer agents.
AID1581358Binding affinity to Cdc37 in human A549 cells assessed as inhibition of HSP90-Cdc37 interaction by measuring decrease in CDK4 protein level at 5 uM incubated for 12 hrs by Western blot analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID1574328Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 296 residues) expressed in Escherichia coli strain Rosetta2 (DE3) by NMR spectroscopy2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1741443Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.
AID1377860Antiproliferative activity against human SKBR3 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID1581382Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 1.2 uM incubated for 48 hrs by Annexin V-FITC and PI staining based flow cytometric analysis (Rvb = 0.5%)2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID1322016Permeability of the compound at pH 7.4 by PAMPA-based pION assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
AID684935Antiarthritic effect in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in RANTES production pre-incubated with compound for 30 mins before stimulation with sonicated-Mtb for 482012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID685082Increase in CCR1 protein surface expression in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model pre-incubated with 0.1 to 0.3 uM compound before stimulation with sonicated Mtb for 24 hrs by flow cytom2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1783332Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.181%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1821524Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID1574321Antiobesity activity in high fat diet-induced obese Ptpn1fl/fl null C57BL/6 mouse treated with rAAV-CMV-Cre-GFP for deletion of PTP1B assessed as reduction in body weight at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1783323Inhibition of P-gp in human A549/Taxol cells assessed as increase in rhodamine 123 accumulation at 0.5 uM preincubated for 4 hrs followed by addition of rhodamine 123 and measured after 1 hr by flow cytometry assay (Rvb = 26.5%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID684689Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in MIP-1alpha production at 200 ug, ip starting from arthritis onset and continued uninterrupted 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID332910Cytotoxicity against human U373 cells after 96 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID332909Cytotoxicity against human ZR-75-1 cells after 72 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID1821525Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID684943Antiarthritic effect in IL-1beta-stimulatedspleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in IL6 production pre-incubated with compound for 30 mins before stimulation with IL-1beta for 48 hrs by multip2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1581355Inhibition of ATP binding to human HSP90 alpha at 5 to 10 uM preincubated for 30 mins followed by gamma phosphate-linked ATP sepharose addition and measured after 30 mins by ATP-binding sepharose assay based western blot analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID606872Inhibition of Hsp90 interaction with [35S]His-tagged HRI K199R mutant in reticulocyte lysate assessed as coadsorbed Hsp90 at 100 uM after 40 mins by SDS-PAGE and Western blot analysis2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID332911Cytotoxicity against human Col2 cells after 96 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID1866624Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
AID1783331Induction of apoptosis in human HepG2 cells assessed as viable cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 99.1%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1808341Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with luciferase reporter plasmid harboring NBRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID332906Cytotoxicity against human KBV1 cells after 72 hrs by sulforhodamine B assay in absence of vinblastine1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID332195Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NF-kappaB activation treated 3 hrs before LPS challenge assessed after 24 hrs by SEAP reporter gene assay2002Journal of natural products, Jan, Volume: 65, Issue:1
Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production.
AID1377231Induction of morphological changes in HEK293 cells assessed as cell shrinkage at 100 uM2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1808323Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NurRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase r2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1225628Inhibition of HSP90 in human MCF7 cells assessed as disruption of interaction with Cdc37 at 5 times IC50 after 24 hrs by co-immunoprecipitation assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1821522Antiproliferative activity against human A-172 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID606953Effect on [35S]His-tagged HRI stability in heme-deficient reticulocyte lysate assessed as loss of [35S]His-tagged HRI at 100 uM after 45 mins by SDS-PAGE and autoradiography2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1380061Non-competitive inhibition of Aspergillus fumigatus N-terminal 6His-tagged SidA expressed in Escherichia coli BL21 (DE3) using L-ornithine as substrate after 20 mins by UPLC analysis2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID684932Antiarthritic effect in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in GRO/KC production pre-incubated with compound for 30 mins before stimulation with sonicated-Mtb for 482012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1873257Anti-obesity activity in male C57BL/6 mouse model of high-fat diet induced obesity assessed as body weight change at 0.1 mg/kg, ip administered once a day for 3 weeks relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
AID463922Inhibition of 3C-like protease of SARS coronavirus assessed as concentration of FRET peptide for 60 mins by dixon plot2010Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.
AID1389862Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
AID1866621Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 0.5 uM incubated for 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.82%)
AID1783334Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.725%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID356593Cytotoxicity against human 1A9 cells after 6 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID1574301Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 296 residues) expressed in Escherichia coli strain Rosetta2 (DE3) up to 500 uM using pNPP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mi2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID636744Induction of HSF1 expression in human NCI-H460 cells at 1 uM after 24 hrs by Western blotting relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Diarylheptanoids from the seeds of Alpinia katsumadai as heat shock factor 1 inducers.
AID1868758Induction of apoptosis in human BGC-823 cells assessed as late apoptotic cells at 1 uM incubated for 24 hrs by annexin-V-FITC and PI staining based flow cytometry analysis (Rvb = 0.6%)
AID1783319Selectivity index, ratio of IC50 for human CCD 19Lu cells to IC50 for human HePAD38 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID356589Cytotoxicity against human U87MG cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID332900Cytotoxicity against human BC1 cells after 72 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID551435Inhibition of recombinant HePTP2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.
AID1596469Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 2 uM incubated for 24 hrs by AnnexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 4.1%)
AID1783314Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1378432Activation of HSF1 in human NCI-H460 cells assessed as upregulation of HSP70 protein levels at 1 uM after 12 hrs by Western blot analysis2017Journal of natural products, 08-25, Volume: 80, Issue:8
The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection.
AID1808328Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NurRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase repor2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID684925Antiarthritic effect in Lewis rat adjuvant-induced arthritis model synovial infiltrating cells restimulated with sonicated Mtb post isolation assessed as reduction in GRO/KC production at 200 ug, ip starting from arthritis onset and continued uninterrupte2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID684928Antiarthritic effect in Lewis rat adjuvant-induced arthritis model synovial infiltrating cells restimulated with sonicated Mtb post isolation assessed as reduction in TNFalpha production at 200 ug, ip starting from arthritis onset and continued uninterrup2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1322012Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
AID1597521Induction of apoptosis in TNFalpha-treated human HepG2 cells assessed as normal cells at 2 uM incubated for 10 hrs by FITC Annexin V and propidium iodide staining based flow cytometric analysis (Rvb = 88.37%)2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID1808329Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NBRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase report2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1808337Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with luciferase reporter plasmid harboring NBRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene a2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1377857Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID1783320Selectivity index, ratio of IC50 for human L02 cells to IC50 for human HepG2 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1866108Inhibition of SHP2 (unknown origin)2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
AID1868751Induction of apoptosis in human BGC-823 cells assessed as viable cells at 1 uM incubated for 24 hrs by annexin-V-FITC and PI staining based flow cytometry analysis (Rvb = 96.3%)
AID684940Antiarthritic effect in IL-1beta-stimulatedspleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in MIP-1alpha production pre-incubated with compound for 30 mins before stimulation with IL-1beta for 48 hrs by2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1506865Binding affinity to N-terminal GST-tagged HSP90 (unknown origin) expressed in Escherichia coli by biolayer interferometry analysis2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1377858Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID636746Induction of HSP70 expression in human NCI-H460 cells at 1 uM after 24 hrs by Western blotting relative to control2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Diarylheptanoids from the seeds of Alpinia katsumadai as heat shock factor 1 inducers.
AID684942Antiarthritic effect in IL-1beta-stimulatedspleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in TNFalpha production pre-incubated with compound for 30 mins before stimulation with IL-1beta for 48 hrs by m2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1424352Cytotoxicity in human BCP-ALL cells assessed as reduction in cell viability2017European journal of medicinal chemistry, Dec-15, Volume: 142Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
AID1378436Cytotoxicity against human L-132 cells assessed as reduction in cell viability up to 20 uM after 24 hrs by MTT assay2017Journal of natural products, 08-25, Volume: 80, Issue:8
The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection.
AID1574314Inhibition of human SHP1 (245 to 521 residues) expressed in Escherichia coli strain BL21(DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID684681Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in CCR2 expression at 200 ug, ip starting from arthritis onset and continued uninterrupted until 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1574289Antiobesity activity in high fat diet-induced obese Ptpn1fl/fl null C57BL/6 mouse assessed as hypophagia at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID684926Antiarthritic effect in Lewis rat adjuvant-induced arthritis model synovial infiltrating cells restimulated with sonicated Mtb post isolation assessed as reduction in MCP1 production at 200 ug, ip starting from arthritis onset and continued uninterrupted 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1574287Antiobesity activity in high fat diet-induced obese Ptpn2fl/fl null C57BL/6 mouse assessed as reduction in body weight at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID356591Cytotoxicity against human 1A9 cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID1783315Cytotoxicity against human L02 cells assessed as cell viability measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1454165Toxicity in nude mouse xenografted with human A549 cells assessed as induction of mouse fatality at 12 mg/kg, ig dosed every day2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID313987Growth inhibition of human RPMI8226 cells2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Antimitotic quinoid triterpenes from Maytenus chuchuhuasca.
AID684914Antiarthritic effect in Lewis rat adjuvant-induced arthritis model serum assessed as reduction in TNFalpha production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study end by cytokine multiplex assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1903927Antitumor activity against human A549 cells xenografted in BALB/c mouse lung tumor model assessed as tumor inhibition rate at 1 mg/kg, ip measured every day for 21 days by caliper method relative to control
AID1596468Induction of apoptosis in human A549 cells assessed as viable cells at 2 uM incubated for 24 hrs by AnnexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 88.1%)
AID1256007Cytotoxicity against human L-132 cells assessed as cell viability at 1 to 8 uM after 12 hrs by MTT assay2015Journal of natural products, Oct-23, Volume: 78, Issue:10
Chalcones from Angelica keiskei: Evaluation of Their Heat Shock Protein Inducing Activities.
AID1581352Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID632313Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Alkaloids from Chelidonium majus and their inhibitory effects on LPS-induced NO production in RAW264.7 cells.
AID1821528Induction of apoptosis in human U-251 cells assessed as chromatin condensation at 0.5 to 2 uM measured after 48 hrs by Hoechst 33342 staining based confocal fluorescence microscopic analysis2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID1529758Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 1.2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.5%)
AID1778385Solubility of the compound in water measured by UV-Visible spectral analysis2021European journal of medicinal chemistry, Aug-05, Volume: 220Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway.
AID1597532Ratio of mortality rate for celastrol to mortality rate for test compound for zebrafish embryo AB at 0.5 uM incubated for 24 hrs2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID332902Cytotoxicity against human Lu1 cells after 72 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID222469Compound was tested for inhibitory effect on LPS-stimulated TNF-alpha release from human monocytes1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine.
AID1377240Inhibition of RGS17 (unknown origin)-mediated CREB phosphorylation2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1380060Non-competitive inhibition of Aspergillus fumigatus N-terminal 6His-tagged SidA expressed in Escherichia coli BL21 (DE3) by FP assay2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID428046Cytoprotection against oxygen-glucose deprivation-induced cytotoxicity in human SH-SY5Y cells at 2.5 uM after 28 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID1808436Binding affinity to Nur77 LBD (unknown origin) expressed in Escherichia coli incubated for 3 hrs by circular dichroism analysis2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID401066Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum NF54 infected human erythrocytes as [3H]hypoxanthine uptake1998Journal of natural products, Jun-26, Volume: 61, Issue:6
Novel quinone methides from Salacia kraussii with in vitro antimalarial activity.
AID1377237Growth inhibition of E-cadherin expressing human PC3 cells after 1 hr by sulforhodamine B assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1377238Growth inhibition of human RWPE1 cells at 31.6 to 56.2 uM after 1 hr by sulforhodamine B assay2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1783333Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.016%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1783327Induction of apoptosis in human L02 cells assessed as viable cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 97.5%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1597526Binding affinity to Myc-Nur77 (unknown origin) expressed in human HepG2 cells co-transfected with Flag tagged TRAF2 assessed as effect on protein interaction with TRAF2 at 2 uM incubated for 1 hr in presence of TNFalpha by co-immunoprecipitation assay2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID356585Cytotoxicity against human MCF7 cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID1574291Antiobesity activity in high fat diet-induced obese Ptpn1fl/fl/Ptpn2fl/fl null C57BL/6 mouse assessed as hypophagia at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1191650Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by Griess reaction based method2015Bioorganic & medicinal chemistry letters, Mar-01, Volume: 25, Issue:5
Anti-inflammatory activity of phenolic compounds from the whole plant of Scutellaria indica.
AID1225607Inhibition of HSP90 in human MCF7 cells assessed as Her2 degradation at 5 times IC50 after 24 hrs by Western blot analysis2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1225613Inhibition of HSP90 in human MCF7 cells assessed as induction of heat shock response-mediated HSP70 production at 5 times IC50 after 24 hrs by Western blot analysis relative to vehicle-treated control2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID684929Antiarthritic effect in Lewis rat adjuvant-induced arthritis model synovial infiltrating cells restimulated with sonicated Mtb post isolation assessed as reduction in IL-1beta production at 200 ug, ip starting from arthritis onset and continued uninterrup2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID684920Antiarthritic effect in Lewis rat adjuvant-induced arthritis model lymph node cells restimulated with sonicated Mtb post isolation assessed as reduction in RANTES production at 200 ug, ip starting from arthritis onset and continued uninterrupted until stu2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1903926Antitumor activity against human A549 cells xenografted in BALB/c mouse lung tumor model assessed as tumor weight at 1 mg/kg, ip measured every day for 21 days by caliper method
AID1675571Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay2020Journal of natural products, 09-25, Volume: 83, Issue:9
Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents.
AID1879837Antiproliferative activity against human L02 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
AID1506862Inhibition of N-terminal GST-tagged HSP90 ATPase activity (unknown origin) expressed in Escherichia coli at 10 uM after 1 hr in presence of ATP by spectrophotometric assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1596470Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 2 uM incubated for 24 hrs by AnnexinV-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 4.2%)
AID1529759Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 1.2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.4%)
AID1324617Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 5 uM after 24 hrs by dual luciferase reporter gene assay2016ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
Identification of Triptophenolide from
AID684688Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in IL6 production at 200 ug, ip starting from arthritis onset and continued uninterrupted until s2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1454175Antitumor activity against human A549 cells xenografted in nude mouse assessed as tumor growth inhibition at 12 mg/kg, ig dosed every day2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1574306Binding affinity to human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) assessed as association half life using DiFMUP as substrate preincubated for 10 mins followed by substrate addi2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1201762Anticancer activity against human SMMC7721 cells assessed as cell survival after 48 hrs by MTT assay2015European journal of medicinal chemistry, May-05, Volume: 95Design and synthesis of celastrol derivatives as anticancer agents.
AID1574309Inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 393 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins in prese2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID684683Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in GRO/KC production at 200 ug, ip starting from arthritis onset and continued uninterrupted unti2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1201765Inhibition of telomerase in human MGC803 cell extracts after 24 hrs by TRAP-PCR-ELISA2015European journal of medicinal chemistry, May-05, Volume: 95Design and synthesis of celastrol derivatives as anticancer agents.
AID1868736Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
AID332905Cytotoxicity against human KBV1 cells after 72 hrs by sulforhodamine B assay in presence of vinblastine1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID1868754Induction of apoptosis in human BGC-823 cells assessed as early apoptotic cells at 1 uM incubated for 24 hrs by annexin-V-FITC and PI staining based flow cytometry analysis (Rvb = 2.4%)
AID1873258Anti-obesity activity in male C57BL/6 mouse model of high-fat diet induced obesity assessed as body weight change at 10 mg/kg, po administered once a day for 3 weeks relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
AID1424353Cytotoxicity in human T-ALL cells assessed as reduction in cell viability2017European journal of medicinal chemistry, Dec-15, Volume: 142Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
AID1597524Binding affinity to purified Nur77 LBD (unknown origin) by SPR analysis2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID1808346Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with luciferase reporter plasmid harboring NBRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene as2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1501725Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.
AID684944Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in CCR3 expression at 200 ug, ip starting from arthritis onset and continued uninterrupted until 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1454169Toxicity in nude mouse xenografted with human A549 cells assessed as change in body weight at 12 mg/kg, ig dosed every day (Rvb = 26.5 g)2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1574316Inhibition of human PTPRE (107 to 707 residues) expressed in Escherichia coli strain BL21(DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID684917Antiarthritic effect in Lewis rat adjuvant-induced arthritis model serum assessed as reduction in IL6 production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study end by cytokine multiplex assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1808345Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with luciferase reporter plasmid harboring NBRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene as2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1597531Toxicity in zebrafish embryo AB assessed as mortality at 0.5 uM incubated for 24 hrs2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID684937Antiarthritic effect in sonicated Mtb-stimulated spleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in IL6 production pre-incubated with compound for 30 mins before stimulation with sonicated-Mtb for 48 hr2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID90824Inhibitory activity against LPS-stimulated 1L-1beta release by cultured human monocytes1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
Novel cytokine release inhibitors. Part I: Triterpenes.
AID1574324Covalent binding to human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) by mass spectrometry2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1808334Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NBRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase rep2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1873241Anti-obesity activity in male C57BL/6 mouse model of high-fat diet induced obesity assessed as body weight change at 3 mg/kg, po administered once a day for 8 weeks relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
AID1879842Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
AID1322010Inhibition of His-tagged full length Hsp90/GST-tagged Cdc37 middle domain (unknown origin) interaction at 50 uM after 1 hr by TR-FRET assay relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
AID1225606Inhibition of HSP90 in human MCF7 cells assessed as pAkt degradation at 5 times IC50 after 24 hrs by Western blot analysis2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1377242Binding affinity to RGS17 (unknown origin) assessed as molecular weight of covalent adduct at 100 uM after 72 hrs by ESI-MS analysis (Rvb = 16232 Da)2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1574311Inhibition of human N-terminal His6-tagged TCPTP catalytic domain (1 to 336 residues) expressed in Escherichia coli strain Rosetta2 (DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins in prese2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID626500Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Inhibitory effect on NO production of phenolic compounds from Myristica fragrans.
AID1424351Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability2017European journal of medicinal chemistry, Dec-15, Volume: 142Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
AID1596416Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability at 1 uM incubated for 48 hrs by MTT assay relative to control
AID392677Neuroprotection against beta-amyloid peptide 1-42-induced toxicity in human SH-SY5Y cells assessed as lactate dehydrogenase release2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line.
AID1225609Inhibition of HSP90 in human MCF7 cells assessed as Raf degradation at 5 times IC50 after 24 hrs by Western blot analysis2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1377228Inhibition of Galphao interaction with GFP-fused RGS17 (unknown origin) deltaN mutant expressed in HEK293 cells assessed as increase in RGS17 deltaN mutant localization at cytoplasm at 10 uM up to 5 mins by confocal microscopic analysis2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1574318Inhibition of mouse LMPTP-A (1 to 158 residues) expressed in Escherichia coli strain BL21(DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1501728Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds.
AID1597528Induction of apoptosis in TNFalpha-treated human HepG2 cells assessed as non-viable apoptotic cells at 2 uM incubated for 10 hrs by FITC Annexin V and propidium iodide staining based flow cytometric analysis (Rvb = 6.65%)2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID684946Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in CCR6 expression at 200 ug, ip starting from arthritis onset and continued uninterrupted until 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID684913Antiarthritic effect in Lewis rat adjuvant-induced arthritis model serum assessed as reduction in RANTES production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study end by cytokine multiplex assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1783316Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1529753Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
AID489310Cytoprotective activity against t-BPH-induced cell damage in rat PC12 cells assessed as cell viability at 1.6 uM2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
Synthesis and preliminary evaluation of neuroprotection of celastrol analogues in PC12 cells.
AID1377859Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID527505Induction of apoptosis in TRAIL-resistant human SW620 cells assessed as pro-apoptotic cells at 50 uM after 24 hrs by annexin-V staining2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis of exotic polycycles such as cyclooctatrienes and fenestrenes with differential pro-apoptotic activities on human TRAIL-resistant metastatic cell lines.
AID1783329Induction of apoptosis in human L02 cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin-V/PI staining based flow cytometry assay (Rvb = 0.133%)2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1821520Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID1454160Cytotoxic activity against human HeLa cells incubated for 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1506876Inhibition of HSP90/Cdc37 protein-protein interaction in human SKBR3 cells assessed as decrease in CDK4 level after 24 hrs by Western blot analysis2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1529752Antiproliferative activity against human HOS cells after 48 hrs by MTT assay
AID1778386Inhibition of hypoxia-induced HIF1alpha transcriptional activity in human Hep3B cells co-transfected with luciferase reporter plasmid containing six copies of HREs and pRL-CMV vector assessed as reduction in luciferase activity incubated for 24 hrs under 2021European journal of medicinal chemistry, Aug-05, Volume: 220Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway.
AID1454161Cytotoxic activity against human HepG2 cells incubated for 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1225611Change in p23 expression in human MCF7 cells at 5 times IC50 after 24 hrs by Western blot analysis2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID684912Antiarthritic effect in Lewis rat adjuvant-induced arthritis model serum assessed as reduction in GRO/KC production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study end by cytokine multiplex assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1868737Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
AID685077Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in CXCR1 expression at 200 ug, ip starting from arthritis onset and continued uninterrupted until2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1377243Inhibition of Galphao interaction with GFP-fused RGS17 (unknown origin) deltaN mutant expressed in HEK293 cells assessed as increase in RGS17 deltaN mutant localization at cytoplasm at 10 uM up to 20 mins by confocal microscopic analysis2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID684930Antiarthritic effect in Lewis rat adjuvant-induced arthritis model synovial infiltrating cells restimulated with sonicated Mtb post isolation assessed as reduction in IL6 production at 200 ug, ip starting from arthritis onset and continued uninterrupted u2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1903910Antiproliferative activity against human U2OS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
AID1596418Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1903911Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
AID1808342Modulation of full length human Nurr1 expressed in PC12 cells co-transfected with luciferase reporter plasmid harboring NBRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID684941Antiarthritic effect in IL-1beta-stimulatedspleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in RANTES production pre-incubated with compound for 30 mins before stimulation with IL-1beta for 48 hrs by mul2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1581383Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 1.2 uM incubated for 48 hrs by Annexin V-FITC and PI staining based flow cytometric analysis (Rvb = 3.0%)2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID1754173Selectivity index, ratio of IC50 for inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 to IC50 for inhibition of recombinant human TDO2 expressed in Escherichia coli BL21 (DE3)
AID684684Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in MCP1 production at 200 ug, ip starting from arthritis onset and continued uninterrupted until 2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID674392Inhibition of LPS-stimulated NFkappaB activation transfected in mouse RAW264.7 cells after 18 hrs by luciferase reporter gene assay2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Myxobacteria versus sponge-derived alkaloids: the bengamide family identified as potent immune modulating agents by scrutiny of LC-MS/ELSD libraries.
AID1581384Induction of apoptosis in human A549 cells assessed as necrotic cells at 1.2 uM incubated for 48 hrs by Annexin V-FITC and PI staining based flow cytometric analysis (Rvb = 1.0%)2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID1574288Antiobesity activity in high fat diet-induced obese Ptpn1fl/fl/Ptpn2fl/fl null C57BL/6 mouse assessed as reduction in body weight at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID684686Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in TNFalpha production at 200 ug, ip starting from arthritis onset and continued uninterrupted un2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1581381Induction of apoptosis in human A549 cells assessed as viable cells at 1.2 uM incubated for 48 hrs by Annexin V-FITC and PI staining based flow cytometric analysis (Rvb = 95.5%)2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID1808324Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NurRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase r2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1754168Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate incubated for 30 mins by methylene blue reagent based concurrent assay
AID1377863Selectivity index, ratio of IC50 for human BJ cells to IC50 for human MIAPaCa2 cells2017European journal of medicinal chemistry, Sep-29, Volume: 138Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation.
AID1574300Inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) up to 500 uM using pNPP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mi2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID90809Compound was evaluated for inhibition of Interleukin (IL1-beta) release in human monocytes.1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
Novel cytokine release inhibitors. Part II: Steroids.
AID1225629Inhibition of HSP90 in human MCF7 cells assessed as disruption of interaction with p23 at 5 times IC50 after 24 hrs by co-immunoprecipitation assay2015Journal of natural products, Apr-24, Volume: 78, Issue:4
Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID356590Cytotoxicity against human PC3 cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID684919Antiarthritic effect in Lewis rat adjuvant-induced arthritis model lymph node cells restimulated with sonicated Mtb post isolation assessed as reduction in MCP1 production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1808291Cytotoxicity against human HEK293T cells assessed as reduction in cell viability at 1.56 to 6.25 microM incubated for 18 hrs by Cell titer-glo assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID684939Antiarthritic effect in IL-1beta-stimulatedspleen adherent cells isolated from Lewis rat adjuvant-induced arthritis model assessed as reduction in MCP1 production pre-incubated with compound for 30 mins before stimulation with IL-1beta for 48 hrs by multi2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1879839Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
AID1574290Antiobesity activity in high fat diet-induced obese Ptpn2fl/fl null C57BL/6 mouse assessed as hypophagia at 100 ug/kg, ip for 10 consecutive days2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1424355Cytotoxicity in human HL60 cells assessed as reduction in cell viability2017European journal of medicinal chemistry, Dec-15, Volume: 142Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
AID1454159Cytotoxic activity against human SGC7901 cells incubated for 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities.
AID1879841Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
AID527507Induction of apoptosis in TRAIL-resistant human THP1 cells after 24 hrs by annexin-V staining2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis of exotic polycycles such as cyclooctatrienes and fenestrenes with differential pro-apoptotic activities on human TRAIL-resistant metastatic cell lines.
AID1808289Cytotoxicity against human SKNBE(2) cells assessed as reduction in cell viability at 1.56 to 6.25 microM incubated for 18 hrs by Cell titer-glo assay2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1821538Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth at 0.25 to 4 uM by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID1783313Antiproliferative activity against human BEAS-2B cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID1378431Activation of HSF1 in human NCI-H460 cells assessed as upregulation of HSP25 protein levels at 1 uM after 12 hrs by Western blot analysis2017Journal of natural products, 08-25, Volume: 80, Issue:8
The Conjugated Double Bond of Coniferyl Aldehyde Is Essential for Heat Shock Factor 1 Mediated Cytotoprotection.
AID1574327Binding affinity to human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) by NMR spectroscopy2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1506864Inhibition of GA-FITC binding to N-terminal GST-tagged HSP90 (unknown origin) expressed in Escherichia coli at 10 uM after 30 mins fluorescence polarization assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID1868739Antiproliferative activity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
AID567627Inhibition of HSP90 in human MCF7 cells assessed as degradation of Hsp70 protein up to 50 uM after 48 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID1604463Antiproliferative activity against human PANC1 cells after 24 hrs by MTS assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
AID332907Cytotoxicity against human A431 cells after 72 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID1574315Inhibition of human SHP2 (246 to 527 residues) expressed in Escherichia coli strain BL21(DE3) using DiFMUP as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by fluorescence assay2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID1581357Binding affinity to Cdc37 in human A549 cells assessed as inhibition of HSP90-Cdc37 interaction by measuring decrease in Akt phosphorylation level at 5 uM incubated for 12 hrs by Western blot analysis2019Journal of medicinal chemistry, 12-12, Volume: 62, Issue:23
Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
AID1783318Selectivity index, ratio of IC50 for human L02 cells to IC50 for human HePAD38 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.
AID313986Inhibition of tubulin polymerization2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
Antimitotic quinoid triterpenes from Maytenus chuchuhuasca.
AID1903925Antiproliferative activity against human A549 cells expressing Cdc37 protein assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
AID1675570Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay2020Journal of natural products, 09-25, Volume: 83, Issue:9
Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents.
AID1506859Inhibition of full length His-tagged HSP90/GST-tagged Cdc37 (unknown origin) interaction at 100 uM after 1 hr by HTRF assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
AID401065Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected human erythrocytes as [3H]hypoxanthine uptake1998Journal of natural products, Jun-26, Volume: 61, Issue:6
Novel quinone methides from Salacia kraussii with in vitro antimalarial activity.
AID1597533Toxicity in zebrafish embryo AB assessed as mortality at 0.5 uM incubated for 72 hrs relative to control2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID1808332Modulation of full length human Nurr1 expressed in HEK293T cells co-transfected with RXRalpha and luciferase reporter plasmid harboring NurRE response element assessed as increase in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase re2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1556982Selectivity index, ratio of IC50 for human IOSE-80 cells to IC50 for human SKOV3 cells2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents.
AID718316Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide generation incubated for 24 hrs2012Journal of natural products, Dec-28, Volume: 75, Issue:12
Phenolic compounds from Caesalpinia sappan heartwood and their anti-inflammatory activity.
AID1754169Inhibition of recombinant human TDO2 expressed in Escherichia coli BL21 (DE3) assessed as reduction in N-formylkynurenine formation using L-tryptophan as substrate incubated for 30 mins by methylene blue reagent based concurrent assay
AID1741445Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Oct-15, Volume: 204Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators.
AID428041Cytotoxicity against human HeLa cells after 72 hrs by MTS assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID1866629Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation measured after 24 to 72 hrs by MTT assay
AID685080Increase in CCR1 expression in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation at 200 ug, ip starting from arthritis onset and continued uninterrupted until study end by qPCR relative baselin2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1879843Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.
AID428034Amplification of HSF1 transcriptional activity in human heat shock-induced HeLa cells assessed as granule formation treated 1 hr before heat shock challenge measured after 2 hrs without recovery time by immunocytochemical staining2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives as novel small molecule chaperone amplifiers.
AID1821519Antiproliferative activity against human U-251 cells assessed as inhibition of cell viability at 0.5 uM measured after 72 hrs by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID551432Inhibition of recombinant SHP22011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.
AID684915Antiarthritic effect in Lewis rat adjuvant-induced arthritis model serum assessed as reduction in IL-1beta production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study end by cytokine multiplex assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1377219Binding affinity to RGS17 (unknown origin) assessed as change in melting temperature by differential scanning fluorimetry2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID1903908Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
AID1574302Reversible inhibition of human N-terminal His6-tagged PTP1B catalytic domain (1 to 298 residues) expressed in Escherichia coli strain Rosetta2 (DE3) at 10 times IC50 using DiFMUP as substrate preincubated for 30 mins followed by 100 fold compound dilution2018Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24
Celastrol Promotes Weight Loss in Diet-Induced Obesity by Inhibiting the Protein Tyrosine Phosphatases PTP1B and TCPTP in the Hypothalamus.
AID527508Induction of apoptosis in TRAIL-resistant human THP1 cells assessed as inhibition of caspase-8 activity2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
Synthesis of exotic polycycles such as cyclooctatrienes and fenestrenes with differential pro-apoptotic activities on human TRAIL-resistant metastatic cell lines.
AID567636Inhibition of HSP90 in human MCF7 cells assessed as degradation of Her2 protein after 48 hrs by Western blotting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
A systematic protocol for the characterization of Hsp90 modulators.
AID332901Cytotoxicity against human HT1080 cells after 48 hrs by sulforhodamine B assay1994Journal of natural products, Jan, Volume: 57, Issue:1
Quinone-methide triterpenes and salaspermic acid from Kokoona ochracea.
AID1597535Toxicity in zebrafish embryo AB assessed as mortality at 0.125 uM incubated for 24 hrs relative to control2019European journal of medicinal chemistry, Sep-01, Volume: 177SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway.
AID684916Toxicity in Lewis rat adjuvant-induced arthritis model serum assessed as increase in MCP1 production at 200 ug, ip starting from arthritis onset and continued uninterrupted until study end by cytokine multiplex assay2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID684685Antiarthritic effect in Lewis rat adjuvant-induced arthritis model spleen adherent cells restimulated with sonicated Mtb post isolation assessed as reduction in RANTES production at 200 ug, ip starting from arthritis onset and continued uninterrupted unti2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Suppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokines.
AID1322013Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
AID1596420Inhibition of Hsp90-Cdc37 interaction in human A549 cells assessed as decrease in Cdc37 protein level at 5 uM incubated for 6 hrs by immunoprecipitation assay
AID606788Inhibition of Hsp90-dependent refolding of luciferase in reticulocyte lysate by microplate reader2011Journal of natural products, May-27, Volume: 74, Issue:5
Gambogic acid, a natural product inhibitor of Hsp90.
AID1424354Cytotoxicity in human Daudi cells assessed as reduction in cell viability2017European journal of medicinal chemistry, Dec-15, Volume: 142Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.
AID1556978Antiproliferative activity against human SKOV3 cells incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Oct-01, Volume: 179Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents.
AID1377234Growth inhibition of human A549 cells measured every 2 hrs over 6 days by live cell imaging based method2017Journal of natural products, 07-28, Volume: 80, Issue:7
Natural Products Discovered in a High-Throughput Screen Identified as Inhibitors of RGS17 and as Cytostatic and Cytotoxic Agents for Lung and Prostate Cancer Cell Lines.
AID356592Cytotoxicity against human 1A9/PTX10 cells after 3 days by SRB assay2003Journal of natural products, Nov, Volume: 66, Issue:11
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii.
AID1808335Modulation of full length human Nurr1 expressed in SKNBE(2) cells co-transfected with luciferase reporter plasmid harboring NurRE response element assessed as decrease in luciferase activity at 1.56 to 6.25 uM incubated for 18 by luciferase reporter gene 2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Assessment of NR4A Ligands That Directly Bind and Modulate the Orphan Nuclear Receptor Nurr1.
AID1821535Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth measured upto 72 hrs by MTT assay2022European journal of medicinal chemistry, Feb-05, Volume: 229Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794863Fluorometric Ub-AMC Hydrolysis Assay from Article 10.1021/acschembio.7b00543: \\Cell Lysate-Based AlphaLISA Deubiquitinase Assay Platform for Identification of Small Molecule Inhibitors.\\2017ACS chemical biology, 09-15, Volume: 12, Issue:9
Cell Lysate-Based AlphaLISA Deubiquitinase Assay Platform for Identification of Small Molecule Inhibitors.
AID1802216ADP-TAMRA Binding Assay from Article 10.1021/acschembio.6b00666: \\Inhibition of the Flavin-Dependent Monooxygenase Siderophore A (SidA) Blocks Siderophore Biosynthesis and Aspergillus fumigatus Growth.\\2016ACS chemical biology, 11-18, Volume: 11, Issue:11
Inhibition of the Flavin-Dependent Monooxygenase Siderophore A (SidA) Blocks Siderophore Biosynthesis and Aspergillus fumigatus Growth.
AID1802217SidA Activity Assay from Article 10.1021/acschembio.6b00666: \\Inhibition of the Flavin-Dependent Monooxygenase Siderophore A (SidA) Blocks Siderophore Biosynthesis and Aspergillus fumigatus Growth.\\2016ACS chemical biology, 11-18, Volume: 11, Issue:11
Inhibition of the Flavin-Dependent Monooxygenase Siderophore A (SidA) Blocks Siderophore Biosynthesis and Aspergillus fumigatus Growth.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (873)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (0.23)18.7374
1990's16 (1.83)18.2507
2000's73 (8.36)29.6817
2010's499 (57.16)24.3611
2020's283 (32.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.33 (24.57)
Research Supply Index6.79 (2.92)
Research Growth Index5.97 (4.65)
Search Engine Demand Index103.38 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (61.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.11%)5.53%
Reviews41 (4.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other843 (95.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]